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The prevalence of obesity is increasing at an alarming rate in allage groups worldwide.
Obesity is a serious health problem due to increased risk of morbidity and mortality.
Although environmental factors play a major role in the development of obesity, the
identification of rare monogenic defects in human genes have confirmed that obesity has a
strong genetic component. Mutations have been identified in genes encoding proteins of
the leptin-melanocortin signaling system, which has an important role in the regulation of
appetite and energy balance.
The present study aimed at identifying mutations and genetic variations in the
melanocortin receptors 2-5 and other genes active on the same signaling p thway
accounting for severe early-onset obesity in children and morbid obesity in adults.
The main achievement of this thesis was the identification of melanocortin-4
receptor (MC4R) mutations in Finnish patients. Six pathogenic MC4R mutations (308delT,
P299H, two S127L and two -439delGC mutations) were identified, corresponding to a
prevalence of 3% in severe early-onset obesity. No obesity causing MC4Rmutations were
found among patients with adult-onset morbid obesity. The MC4R 308delT deletion is
predicted to result in a grossly truncated nonfunctional receptor of only 107 amino acids.
The C-terminal residues, which are important in MC4R cell surface t rgeting, are totally
absent from the mutant 308delT receptor. In vitro functional studies supported a
pathogenic role for the S127L mutation since agonist induced signaling of the receptor was
impaired. Cell membrane localization of the S127L receptor did not differ from that of the
wild-type receptor, confirming that impaired function of the S127L receptor was due to
reduced signaling properties. The P299H mutation leads to intracellular retention of the
receptor. The -439delGC deletion is situated at a potential nescie t helix-loop-helix 2
(NHLH2) -binding site in the MC4R promoter. It was demonstrated that the transcription
factor NHLH2 binds to the consensus sequence at the -439delGC site in v ro, possibly
resulting in altered promoter activity.
Several genetic variants were identified in the melanocortin-3 receptor (MC3R) and
pro-opiomelanocortin (POMC) genes. These polymorphisms do not explain morbid
obesity, but the results indicate that some of these genetic variations may be modifying
factors in obesity, resulting in subtle changes in obesity-related traits. A risk haplotype for
obesity was identified in the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1)
gene through a candidate gene single nucleotide polymorphism (SNP) genotyping
approach. An ENPP1 haplotype, composed of SNPs rs1800949 and rs943003, was shown
to be significantly associated with morbid obesity in adults. Accordingly, the MC3R,
POMC and ENPP1 genes represent examples of susceptibility genes in which genetic
variants predispose to obesity.
In conclusion, pathogenic mutations in the MC4R gene were shown to account for
3% of cases with severe early-onset obesity in Finland. This is in line with results from
other populations demonstrating that mutations in the MC4R gene underlie 1-6% of morbid
obesity worldwide. MC4R deficiency thus represents the most common monogenic defect
causing human obesity reported so far. The severity of the MC4-receptor d fect appears to
be associated with time of onset and the degree of obesity. Classific tion of MC4R
mutations may provide a useful tool when predicting the outcome of the disease. In
addition, several other genetic variants conferring susceptibility to obesity were detected in




The prevalence of obesity is increasing at an alarming rate in allage groups worldwide
(Kopelman 2000; Hill 2006). Although this trend is largely attributable to environmental
changes, such as decreased physical activity and easy access to high-energy containing
food, adoption and twin studies have clearly demonstrated that obesity has a strong genetic
component (Bell et al. 2005).
During the last ten years there has been remarkable progress in the field of g netics.
The recent advances in genetic research technologies, the completin of the Human
Genome Project (International Human Genome Sequencing Consortium 2004) and the
increasing amount of genetic information publicly available in databases have provided the
basic tools for the identification of disease-related genes. The cloning and characterization
of several mouse obesity genes constitute the basis for current molecular genetic obesity
research and have greatly increased the understanding of the regulation of appetite and
energy balance (Robinson et al. 2000). The identification of rare monogenic defects in the
equivalent human genes, encoding proteins of the leptin-melanocortin signaling system,
has confirmed that obesity genes indeed exist. Functional testing of mutated proteins has
become a prerequisite research tool in the evaluation of the consequencs of a genetic
defect. The knowledge about conserved non-coding sequences is increasing and it is
becoming obvious that regulatory regions containing binding sites for transcription factors
are important in the regulation of gene expression.
Although several genes involved in the regulation of energy balance and appetite
have been identified, the genetic basis of common obesity remains partly unsolved. Over
250 chromosomal loci linked with obesity-related phenotypes and 127 different candidate
genes associated with obesity have been identified (Rankinen et al. 2006) The next goal in
the post-genome era is to further characterize the variation in the human genome and to
identify the factors underlying common, polygenic forms of obesity. The integration of
various techniques and information from several sources, e.g. environmental factors,
genotype information and gene expression data, will provide the means to clarify this field.
The main purpose of the present work was to investigate if severe arly-onset
obesity in children and morbid obesity in adults in Finland can be explained by genetic
variation in the melanocortin receptors 2-5 and other genes active in th  same signaling
pathway.
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REVIEW OF THE LITERATURE
1 OBESITY
1.1 Definition of obesity
Obesity can be defined as an excess of fat tissue resulting from a long term imbalance
between energy intake and expenditure (WHO 1995; WHO 2000). A simple index that is
commonly used in adults to classify obesity is the body mass index (BMI), which is
calculated by dividing the weight in kilograms by the square of the height in meters
(kg/m2). The cut-off points proposed by the World Health Organization (WHO) in the
classification of obesity are shown in Table 1 (WHO 1995; WHO 2000). The classification
is based primarily on the association between BMI and mortality (Manson et al. 1995;
WHO 1995; WHO 2000)
Table 1. Cut-off points in the classification of obesity in adults proposed by the WHO (WHO 1995; WHO
2000).




18.5-24.9 Normal weight Average
25.0-29.9 Overweight Increased
30.0-34.9 Obese class I (Obesity) Moderate
35.0-39.9 Obese class II (Severe obesity) Severe
≥40.0 Obese class III (Morbid obesity) Very severe
The classification of obesity status in children and adolescents is complicated
because their height and body composition is continuously changing. BMI cut-off points
for defining overweight and obesity in children have been proposed by Cole et al. (2000),
but no widely accepted classification criteria for childhood obesity are available at present.
In Finland the recommendation is to use relative weight for height and compare it to age
specific 90. and 98. percentile curves (Table 2) (Sorva et al. 1984). The adult BMI cut-off
points are applicable when growth in height has ended.
Table 2. Cut-off points used in the classification of childood obesity in Finland.
Classification of
obesity
Children of age under 7-years
(weight for height, %)
Children from the age of 7-years - end of growth in
height (weight for height, %)
Overweight 10-20 20-40
Obesity > 20 > 40
Obese individuals with abdominal fat distribution are at high risk for obesity-
associated illnesses (Kissebah and Krakower 1994). Abdominal fat accumulation can be
measured anthropometrically by use of the waist-to-hip ratio (WHR) and waist
circumference (Han et al. 1997; Janssen et al. 2004). More accurate me sures to estimate
body adiposity and fat distribution include e.g. underwater weighing, bioimpedance
analysis, dual-energy X-ray absorptiometry, skinfold thickness, computer tomography,
ultrasound and magnetic resonance imaging (WHO 2000).
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1.2 Epidemiology
The prevalence of obesity and overweight is increasing worldwide at an larming rate
(Kopelman 2000; Hill 2006). The large increase in the prevalence of obesity in the United
States has been documented by the National Health and Nutrition Surveys (Fl gal and
Troiano 2000). The number of obese individuals has doubled since the year 1980 in the
US. Currently over 30% of the adult population can be considered obese (BMI > 30 kg/m2)
and 65% overweight (BMI > 25 kg/m2). The prevalence of morbid obesity (BMI > 40
kg/m2) has increased markedly in the US and is currently 4.7% among the adult pop lation
(Flegal and Troiano 2000). The most comprehensive data on obesity in Europe, collected
between 1983 and 1986, comes from the MONICA study (Keil and Kuulasmaa 1989). At
that time, more than half of the European population was overweight and 15% of men and
22% of women were obese. In Finland, the prevalence of obesity has increased between
years 1982 and 1997 in men from 15.4% to 19.8% and in women from 17.7% to 19.4%
(Lahti-Koski et al. 2000). Morbid obesity in Finland, with a prevalence of 0.5% in men and
1.2% in women, is rare if compared to the figures from the US (Pietinen et al. 1996).
Increasing obesity rates are not problems of Europe and the US alone. The obesity
epidemic is also affecting e.g. Southeast Asia (Popkin 1994), the Pacific region (Bennett
and Magnus 1994; Hodge et al. 1995), Middle East (al-Nuaim et al. 1996) and eve  the
African region (Steyn et al. 1991; Hodge et al. 1996).
Because of the lack of worldwide criteria for the classification of obesity in
childhood and adolescence, there are no global estimates of the prevalence of obesity in
younger age groups (WHO 2000). However, several national studies have reported that the
prevalence of childhood obesity has increased (Freedman et al. 1997; Kotani et al. 1997;
Ogden et al. 2002; Hedley et al. 2004). In the US the number of overweight and obese
children has doubled during the last two decades (Freedman et al. 1997) and the same
development is observed worldwide (Deckelbaum and Williams 2001). The trend is similar
in Finland, the age-standardized prevalence of overweight among adolescents in reased in
boys from 7.2 to 16.7%, and in girls from 4.0 to 9.8% between years 1977 and 1999
(Kautiainen et al. 2002).
1.3 Morbidity and mortality associated with obesity
Obesity is associated with an increased risk of adverse health conseque ces (National Task
Force on the Prevention and Treatment of Obesity 2000; Kopelman 2000). It is a burden to
the public health care system and contributes to health care expenditur s (Seidell 1995;
Colditz 1999; Pekurinen et al. 2000; Anderson et al. 2005). Obesity predisposes to everal
diseases, e.g. type 2 diabetes, coronary heart disease, sleep apnea, strok , gallbladder
disease, liver disease, osteoarthritis, infertility and certain forms of cancer (National Task
Force on the Prevention and Treatment of Obesity 2000; Kopelman 2000). Increased wai t
circumference is associated with increased health risk, even when comparing individuals
with the same BMI (Janssen et al. 2004). Furthermore, abdominal fat distribution is a risk
factor for obesity-associated illness and predisposes for hypertension, dyslipidemia,
hyperinsulinemia and other metabolic disturbances (Kissebah and Krakower 1994).
Obese individuals are at high risk for developing insulin resistance d type 2
diabetes (Kahn et al. 2006). Insulin resistance can be defined as a decreased biological
effect of insulin in target tissues (Kahn 1978), leading to an imbalance i  glucose
homeostasis. In the normal state, insulin stimulates the uptake and use of glucose by
muscle and adipocytes and suppresses glucose production in the liver. This leads to lower
REVIEW OF THE LITERATURE
11
blood glucose levels. Several factors involved in the development of insulin resistance, e.g.
free fatty acids, hormones and cytokines, are secreted by the adipose tissue. In obesity,
increased amounts of these circulating factors together with impaired insulin secretion
results in hyperglycemia and ultimately in type 2 diabetes (Kahn et al. 2006). The
increasing prevalence of obesity is resulting in increased prevalence of the metabolic
syndrome (Eckel et al. 2005), which can be defined as the co-occurrence of obesity-
associated disturbances, e.g. central obesity, insulin resistance, hyp rlipidemia and
hypertension. Individuals with the metabolic syndrome are at high risk for developing type
2 diabetes and cardiovascular disease (Eckel et al. 2005).
Several studies have shown J- or U- shaped relationships between BMI and
mortality, meaning that individuals from both ends of the curve are at high risk (Troiano et
al. 1996). The mortality rate increases markedly with a BMI of at least 30 kg/m2 (Troiano
et al. 1996; Calle et al. 1999) and can be explained by chronic diseases th t occur more
frequently in obese than in lean individuals (Kopelman 2000).
The health effects associated with childhood obesity are similar to those observed
in the adult population (Deckelbaum and Williams 2001). Hypertension, dyslipidemia and
insulin resistance appear frequently in obese pediatric patients (Deckelbaum and Williams
2001). A particular problem is the increasing rates of type 2 diabetes associated with
childhood obesity (Pinhas-Hamiel et al. 1996; Haines et al. 2007). Furthermore, obesity in
childhood and adolescence is a key predictor of obesity in adulthood and increases the risk
of obesity-associated diseases later in life (Goran 2001).
2 STRATEGIES TO STUDY THE GENETIC BACKGROUND OF
OBESITY
2.1 Genetic epidemiology
Obesity is a complex trait, not solely following the rules of Mendelian recessive or
dominant inheritance explained by the effect of a single gene. In complex traits, the
interaction of both genetic and environmental factors predispose to the development of the
disease (Lander and Schork 1994). The first evidence that genetics is involved in the
development of common obesity came from genetic epidemiological twin s udies, giving
high estimates (> 0.78) for the heritability of obesity (Feinleib et al. 1977; Stunkard et al.
1986a). An adoption study performed by Stunkard et al. (1986b) gave similar estimat  on
the heritability of body weight. Clustering of obesity has been observed also in family
studies (Heller et al. 1984; Bouchard et al. 1988). To date, a large number of
epidemiological studies estimating the heritability of obesity have be n published (for
review, see Loos and Bouchard 2003). Different phenotypes, such as weight, BMI, WHR
and skinfold thickness have been used in these studies. In general, these studies have given
somewhat lower estimates for the heritability of obesity than the first twin and adoption
studies. There is growing consensus that the heritability of obesity and body weight is
about 30-40%, depending on the phenotype investigated (Bell et al. 2005).
Genetic epidemiology is an approach for studying the inheritance of a trait, based
on statistical analysis of the distribution of phenotypes in related individuals (Bouchard
1995). In contrast, genotype approaches utilize information of the genetic variation on the
level of deoxyribonucleic acid (DNA). The main strategies to study the gen tic background
of a human trait are genome-wide linkage, candidate gene and genome-wide association
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approaches. Genome-wide association studies are increasingly utilized in successful gene
identification.
2.2 Genome-wide linkage
When there is no pre-existing knowledge about the genes that might underlie a t ait, a
genome wide linkage approach can be used (Terwilliger and Ott 1994). The principle of a
genome scan is to genotype polymorphic markers distributed over the whole gen me.
Traditionally microsatellite markers or other sequence repeats have been used. The degree
of linkage between the markers and a disease trait is statistically calculated in families with
several affected members. By use of linkage analysis it is possible to identify the
chromosomal regions involved in disease susceptibility. If the chromos al region is
transmitted with the disease in families, it is likely that this region contains the gene
involved in the disease pathogenesis. The method has been useful in identifying genetic
regions and genes involved in the pathogenesis of monogenic diseases. However, there are
also examples of identification of genes underlying complex diseases, such a  NOD2 in
inflammatory bowel disease (Ogura et al. 2001) and ADAM33 in asthma (Van Eerdewegh
et al. 2002). In the field of obesity research, more than 250 quantitative rait loci (QTL)
linked with obesity-related phenotypes have been identified (Rankinen et al. 2006). Of
these QTLs identified, 52 were supported by evidence from two or more studies.
Several of these genome scans have studied linkage to BMI in families that were
originally gathered for other purposes, e.g. sample sets for studies of type 2 diabetes,
osteoporosis and hypertension (Bell et al. 2005). These cohorts may not be optimal for
obesity research, as they have not been selected for body weight, BMI or other measures of
adiposity. A sampling strategy useful in obesity research is to gather  sample set with a
significant genetic component for obesity, by selecting families that include several
extremely obese individuals (Bell et al. 2005).
2.3 Candidate gene approach
The candidate gene approach can be applied if there is some pre-existing knowledge about
the disease studied (Tabor et al. 2002). There are two main types of candidate genes.
Positional candidate genes are those that are identified through a genome scan, while
functional candidates are genes that are thought to be involved in the pathogenesis of the
disease. For example, studies with animal models, knowledge about metabolic pathways
and gene expression profiling can provide information of potential functional candidates. A
case-control approach represents the most common type of candidate gene study.
Polymorphic markers are genotyped in the study population within the gene of interest, and
tested for association with the disease. Another possibility is to resequence the gene in the
study population in order to detect all variation within the gene. There are several
examples of successful identification of obesity genes by use of the candidate gene
approach (Rankinen et al. 2006). The latest human obesity gene map update lists 416
different reports of significant associations with 127 candidate genes (Rankinen et al.
2006). The first obesity genes that were identified by use of the positional candidate gene
approach were GAD2 (Boutin et al. 2003) and SLC6A14 (Suviolahti et al. 2003a).
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2.4 Rodent obesity loci and corresponding human genes
Animal models provide a valuable tool for studying the genetic background of complex
traits (Lander and Schork 1994). The murine obesity gene map includes nearly 250 genes
that, when mutated, knocked out or expressed as transgenes, result in phenotypes affecting
body weight and adiposity (Rankinen et al. 2006). Studies with animal models may reveal
homologous human genes or give information about other important genes that are
involved in the same biological pathways (Lander and Schork 1994). The cloning and
characterization of mouse agouti, fat, tubby, obese and diabetes genes have played a
crucial role in obesity research and led to the identification of key neural circuits involved
in the regulation of appetite and energy balance in mice and humans (Robinson et al.
2000). During the last years, several mouse QTLs have been fine mapped using rodent
congenic strains (Rankinen et al. 2006). Several congenic rodent strains expre sing a wide
variety of adiposity and growth are available, providing a platform in which t e analysis of
QTLs is relatively easy. The advantage of studying polygenic obesity in animal models is
that the environmental and genetic backgrounds can be held constant (Barsh et l. 2000).
Additionally, mouse models have been developed in order to assess the question of
interacting, epistatic loci that are suspected to play a major role in the genetics of complex
traits (Warden et al. 2004).
2.5 New research strategies in the post-genome era
During the last ten years there has been a remarkable progress in the f eld of molecular
genetics. The Human Genome Project provided the first draft of the human genome
sequence in 2001 (Lander et al. 2001; Venter et al. 2001) and the remaining sequence gaps
were finished in 2003 (International Human Genome Sequencing Consortium 2004). This
sequence data, as well as information about genetic variation in the form o  millions of
single nucleotide polymorphisms (SNPs) (Sachidanandam et al. 2001), is available in
public databases. The next goal in the post-genome era is to characterize the variation in
the human genome and to identify the factors underlying complex diseases.
After the completion of the Human Genome Project, genomic sequences of s veral
other organisms have also been released. Currently, the National Center for Biotechnology
Information public database contains completed genomic sequences of 605 organisms and
draft sequences of several other species. By comparing the genomes of different species, it
has become apparent that the number of genes in the human genome does not differ
markedly from the number of genes identified in other eukaryotes. The current estimate of
the number of protein coding genes in human genome is around 20,000-25,000
(International Human Genome Sequencing Consortium 2004). There are also remarkable
similarities in intronic and intragenic sequences between species. These conserved
sequences are suspected to contain regions important in the regulation of gene expression,
e.g. binding sites for transcription factors (Pennacchio and Rubin 2001). Informati n about
transcription factor binding sites have been collected in databases, such as TRANSFAC
(Wingender et al. 1996). This information can be used to search for binding sites for
known transcription factors and for analysis of sequence variation detected in non-coding
regions of the genome.
The International HapMap project started in 2002, with the goal of determining
linkage disequilibrium (LD) patterns in the human genome in order to facilitate the
research of complex diseases (The International HapMap Consortium 2003). Most of the
recombinations in the human genome occur at same locations, in recombination hot-spots
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(Gabriel et al. 2002). The SNPs located between the recombination hot-spots are in high
LD with each other and constitute defined blocks in the genome. The variation withi  these
blocks can easily be covered by selecting tag-SNPs. By use of these tag-SNPs it is possible
to achieve maximal information about the genetic variation, with minimal genotyping
efforts (The International HapMap Consortium 2003).
At the same time as a large amount of genetic information has become publicly
available, there has also been enormous progress in SNP genotyping techniques (The
International HapMap Consortium 2003). It is already possible to perf rm genome-wide
association studies, which utilize the combination of association and linkage in gene
identification. This approach has successfully identified loci for age-related macular
degeneration (Klein et al. 2005), type 2 diabetes (Saxena et al. 2007), Alzheimer’s disease
(Coon et al. 2007), nicotine dependence (Uhl et al. 2007) and Crohn’s disease (Libioulle et
al. 2007; Rioux et al. 2007).
The recent development of microarray technology has provided a tool for gathering
information on the simultaneous expression of thousands of genes in the tissue of interest
(Lockhart and Winzeler 2000). In obesity research, this technique can be used to compare
expression profiles from obese and lean individuals and to identify genes that are up- or
downregulated in these physiological states (Bell et al. 2005). Large scal gene expression
profiling and usage of expression data as QTLs has successfully been carri d out in mice
and humans (Schadt et al. 2003; Morley et al. 2004).
3 MONOGENIC ANIMAL MODELS OF SEVERE OBESITY
The cloning and characterization of several mouse obesity genes have played a crucial role
in the field of obesity research and led to the identification of key neural circuits involved
in the regulation of appetite and energy balance in mouse and human (Robinson et al.
2000). Some of the most important obesity mouse models, involved in melanocorti
signaling or otherwise relevant for this thesis, are described in the following paragraphs.
3.1 Leptin (ob/ob) and the leptin receptor (db/db)
The obese (ob/ob) mouse strain presenting with autosomal recessive morbid obesity was
reported in 1950 by Ingalls et al. The diabetes (db/db) mutation, discovered later, results in
an almost identical phenotype as the ob/ob mutation (Coleman 1978). In the 1970’s,
parabiosis experiments were performed with these obese mouse strains. In these
experiments the blood circulatory systems of ob/ob and db/db mice were connected with
those of lean mice (Coleman 1973). The experiments suggested that the ob/ob mice lacked
an adipostatic hormone and the db/db mice the receptor for that hormone (Coleman 1973).
These results were confirmed in the 1990s when the ob and db genes were identified
through positional cloning (Zhang et al. 1994; Tartaglia et al. 1995).
The ob gene encodes a protein belonging to the cytokine family, named leptin,
which is secreted mainly from adipocytes (Zhang et al. 1994). The db gene encodes a
receptor belonging to the family of class I cytokine receptors, which bind leptin with high
affinity (Tartaglia et al. 1995). There are at least six alternatively spliced variants of the
leptin receptor (LEPR), which vary in the length of their cytoplasmic domains (Lee et al.
1996). The long form of LEPR is expressed in hypothalamic regions of brain th t are
involved in the regulation of energy balance (Mercer et al. 1996). Furthermore,
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homodimers of the long form are able to activate the intracellular Janus kinase/signal
transducer and activator of transcription (JAK/STAT) pathway (Baumann et al. 1996;
Ghilardi et al. 1996; Bahrenberg et al. 2002). Activation of the JAK/STAT pathway results
in stimulation of anorexigenic, appetite-decreasing peptides and in inhibition of orexigenic,
appetite-increasing peptides. The soluble short form of LEPR presumably facilitates the
transport of leptin through the blood-brain barrier (Lee et al. 1996; Tartaglia 1997;
Robinson et al. 2000).
The ob/ob and db/db mice present with morbid early-onset obesity, increased
adipose mass, hyperphagia, reduced energy expenditure, hyperglycemia, hyperinsulin mia,
high cortisol levels, hypothyroidism, dyslipidemia, decreased body temperature nd
defective thermogenesis, and infertility due to hypogonadotropic hypogonadism (Friedman
and Halaas 1998). In the ob/ob mice, these abnormalities are corrected by leptin
administration (Halaas et al. 1995). In contrast, the db/db mice are unresponsive to
endogenous and exogenous leptin (Friedman and Halaas 1998).
3.2 Mouse models involved in melanocortin signaling
The first obesity model involved in melanocortin signaling, the lethal yellow/yellow agouti
(Ay) mouse strain, was described a century ago (Danforth and de Aberle 1927). Since then,
several other mutations of the agouti gene: Avy, Asy, Aiy, Ahyv and Aiapy, causing yellow coat
color and obesity, have been described (Yen et al. 1994). These are all promoter mutations
leading to obesity, hyperphagia, hyperinsulinemia, type 2 diabetes, hypercortisolemia,
hyperleptinemia, infertility and increased linear growth. The agouti l cus encodes a small
protein, with a signal peptide part of 22 amino acids (Bultman et al. 1992). Normally,
agouti is expressed in the melanocytes of hair follicles, where it acts in hair pigmentation
by blocking the action of α-melanocyte stimulating hormone (α-MSH) at the melanocortin-
1 receptor (MC1R) (Lu et al. 1994). The mutations in the agouti l cus result in widespread
ectopic overexpression of agouti, which antagonizes MC1R in the hair follicle and MC4R
in the hypothalamus, resulting in yellow coat color and in obesity, respectively (Lu et al.
1994).
Targeted deletion of the Mc4r gene provided evidence that the obesity syndrome in
agouti mice was caused by antagonism of MC4R. Mc4r knockout mice present with a
similar obesity syndrome as agouti mice, but have normal coat color (Huszar et al. 1997).
Mc4r deficient mice are severly obese, hyperphagic and have accelerated longitudinal
growth. Mice lacking both alleles of Mc4r develop a severe obesity syndrome, while
heterozygous mice lacking one Mc4r allele have an intermediate obesity phenotype
(Huszar et al. 1997). In addition to the Mc4r knockout mice, several other transgenic
animal models elucidating the mechanisms of melanocortin signaling have been
developed. For example, pro-opiomelanocortin (Pomc) knockout mice (Yaswen et al.
1999) and transgenic mice overexpressing a hypothalamic homolog of agouti, agouti
related protein (Agrp) (Ollmann et al. 1997), are obese. The natural agonist of MC4R, α-
MSH, is processed from the preprohormone POMC (Yaswen et al. 1999). The Pomc
knockout mice are obese, defective in adrenal development and have yellow coat color
(Yaswen et al. 1999).
The mahogany (mg/mg) and mahoganoid (md/md) mutations are natural
suppressors of Ay-induced yellow pigmentation and the obesity syndrome in agouti mice
(Miller et al. 1997). The mg and md genes are located on different chromosomes, but they
generate the same phenotype, which suggests that the proteins are part of the same
pathway. Because the mutations are not able to suppress the phenotype of Mc1r r Mc4r
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knockout mice, it has been suggested that the proteins would be functional at the same
level or upstream of the melanocortin receptors (Miller et al. 1997). Mahogany is a single-
transmembrane protein with a large extracellular region and short cyt plasmic tail, with no
signaling motifs present (Nagle et al. 1999). The exact function of mahogany is still
unknown, but it has been suggested to facilitate the signaling of melanocorti  receptor
antagonists (Nagle et al. 1999).
The role of the melanocortin-3 receptor (MC3R) in melanocortin signaling was
assessed by generating a Mc3r knockout mouse (Butler et al. 2000). Mice deficient for the
Mc3r gene develop a metabolic syndrome characterized by increased fat mass, reduced
lean body mass and higher feed efficiency (Butler et al. 2000; Chen et al. 2000). The mice
are not significantly overweight, but they are hyperleptinemic due to increased fat mass
and they have shorter bone and body length. A double knockout of the Mc3r and Mc4r
genes was also created in order to understand the differences between these two mouse
models (Chen et al. 2000). These double mutants were significantly heavier than the Mc3r
or the Mc4r deficient mice and it was concluded that these two receptors serve non-
redundant roles in energy homeostasis (Chen et al. 2000).
3.3 Carboxypeptidase E and tubby
The autosomal recessive fat/fat mutation in the carboxypeptidase E gene results in severe
hyperproinsulinemia, i.e. elevated levels of unprocessed insulin, severe ob sity, infertility
and hypoadrenalism (Coleman and Eicher 1990). The carboxypeptidase E gene encodes an
exopeptidase, which acts in the proteolytic maturation process of several hormones and
neuropeptides (Naggert et al. 1995). The exact molecular mechanism by which the
inactivation of carboxypeptidase E leads to obesity in the fat/fat mice is still unclear. It has
been suggested that the weight gain in the fat/fat mice results from defects in the
processing of several hypothalamic neuropeptides controlling energy intake and
expenditure (Naggert et al. 1995; Leibel et al. 1997).
The autosomal recessive mutation tubby (tub/tub) causes maturity-onset obesity
associated with hyperinsulinemia, hyperleptinemia and sensory neural defects (Coleman
and Eicher 1990; Ohlemiller et al. 1995). The tubby gene encodes a protein belonging to
the family of tubby-like proteins (North et al. 1997), that could represent a unique family
of transcription factors (Boggon et al. 1999). The physiologic mechanism for obesity in
tubby mice is not known. It has been suggested that the obesity in tubby mice might result
from apoptosis of hypothalamic neural cells (Kleyn et al. 1996).
3.4 Mouse models involving transcription factors
There is growing evidence concerning the role of several transcription factors involved in
the regulation of energy balance, adipogenesis, thermogenesis and consequently in the
development of obesity (Nilaweera et al. 2002; Liang and Ward 2006; Stienstra et al.
2006).
The nescient helix-loop-helix 2 (NHLH2) is a transcription factor impl cated in the
regulation of energy balance (Nilaweera et al. 2002). Transgenic mice deficient for the
Nhlh2 gene develop severe and progressive adult-onset obesity and reduced fertility due to
hypogonadism (Good et al. 1997). The obesity syndrome is similar to that seen in Mc4r
deficient mice (Jing et al. 2004). Nhlh2 knockout mice have a decreased number of Pomc
expressing neurons in the arcuate nucleus, implicating a possible role for NHLH2 in the
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regulation of POMC production (Nilaweera et al. 2002). Later, it wasdemonstrated that
Nhlh2 deficient mice have decreased levels of α-MSH due to reduced levels of prohormone
convertase 1 (PC1) and PC2 enzymes, which are normally involved in posttranscriptional
processing of POMC (Jing et al. 2004).
Another basic helix-loop-helix transcription factor shown to be involved in the
regulation of energy balance is the homolog of the Drosophila single-minded 1 gene, Sim1.
Mice homozygous for the null allele of Sim1 gene die perinatally and lack the
hypothalamic paraventricular nucleus (PVN) (Michaud et al. 1998). Heterozygous Sim1
mice present with early-onset obesity, increased linear growth, hyperphagia,
hyperinsulinemia and hyperleptinemia (Michaud et al. 2001). Heterozygous Sim1 mice
have lesions in their PVN which are suggested to cause the obesity syndrome (Michaud et
al. 2001).
4 THE LEPTIN-MELANOCORTIN SIGNALING SYSTEM AND ITS
DISORDERS IN HUMAN OBESITY
4.1 The leptin-melanocortin signaling pathway
Leptin is a key hormone in the physiological system regulating food intake and body
weight (Friedman and Halaas 1998). Leptin is produced by adipose tissue, the circulating
levels being proportional to body fat content (Considine et al. 1996). Leptin functions as a
long-term peripheral satiety signal by reporting nutritional information to the brain. Within
the hypothalamus of the brain, the arcuate nucleus, paraventricular nucleus, lateral
hypothalamic area, ventromedial nucleus and dorsomedial nucleus are the most important
areas for regulation of food intake (Hillebrand et al. 2002). In the hypothalamus leptin acts
through the leptin receptor and induces the expression of the anorexic, appetite-decreasing
peptides POMC and cocaine-and-amphetamine-related transcript (CART) (Spiegelman and
Flier 2001). Another group of neurons expresses the orexigenic, appetite-increasing
peptides neuropeptide Y (NPY) and AGRP, which are inhibited by the action of leptin
(Spiegelman and Flier 2001). The leptin-melanocortin signaling pathway is dep cted in
Figure 1.
POMC is processed into several smaller neuropeptides by endoproteolytic cleavage
(Pritchard et al. 2002). This posttranslational modification by prohormone convertases PC1
and PC2 is tissue specific, resulting in different neuropeptides in different parts of the
brain. In the anterior pituitary, PC1 produces adrenocorticotrophic hormone (ACTH) and
β-lipotropin, whereas in the hypothalamus the combined effect of PC1 and PC2 results in
the production of α-, β- and γ-MSH and β-endorphin (Pritchard et al. 2002). Neuropeptides
derived from POMC mediate the signals to a family of melanocortin receptors (MC1R-
MC5R) of which MC4R and MC3R play major roles in the regulation of energy balance
(Spiegelman and Flier 2001). The main agonist for MC4R and MC3R is α-MSH, although
there is growing evidence that α-MSH is not the most abundant form of MSH in the brain
and that other POMC derived peptides could also function as agonists (M llington et al.
2001; Harrold et al. 2003; Nickolls et al. 2003).
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Figure 1. The leptin-melanocortin signaling pathway. Leptin is secreted from adipose tissue and is
transported to the hypothalamus where it binds to the leptin receptor. Pre-prohormone POMC expression
increases. The prohormone convertases PC1 and PC2 cleave POMC enzymatically into several smaller
neuropeptides. Of these neuropeptides α-MSH and β-MSH play a key role in this signaling cascade. The
agonists α-MSH and β-MSH bind to MC4R and MC3R and lead to the activation of the receptors. The
antagonist AGRP acts by inhibiting the function of these receptors. Intracellular cAMP levels increase finally
resulting in decreased appetite.
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Recent data indicate that MC4R exhibits a constitutive activity upon which AGRP
acts as an inverse agonist (Haskell-Luevano and Monck 2001; Nijenhuis et al. 2001;
Srinivasan et al. 2004). It has been demonstrated that MC4R and MC3R are coupled to the
G-protein mediated cyclic adenosine monophosphate (cAMP) pathway (Lee et al. 2001).
The molecular mechanisms producing downstream effects of melanocortin signaling are
not known in detail (Spiegelman and Flier 2001). However, SIM1, brain-derived
neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (TrkB) have
been indicated as potential downstream candidates of melanocortin actio (Gray et al.
2006; Kublaoui et al. 2006; Gray et al. 2007).
The importance of the central melanocortin system in the regulation of energy
balance and appetite has been clearly demonstrated in studies of monogenic animal models
(Carroll et al. 2004). For most genes causing obesity in mouse models, human counterparts
have been identified (Mutch and Clement 2006a). The disorders of the leptin-melanocortin
signaling system in human obesity are presented in the following paragraphs.
4.2 Leptin
In 1997 Montague et al. reported two severely obese cousins from a consanguieous
family with a homozygous frameshift mutation (delG133) in the leptin gene. Five further
patients homozygous for the same mutation and three patients with a homozygous R105W
missense mutation have been described (Farooqi and O'Rahilly 2006). All mutation
carriers are characterized by severe early-onset obesity, intense hyperphagia and food-
seeking behavior. The phenotype of these patients includes hyperinsulinemia, c ntral
hypothyroidism and hypogonadotropic hypogonadism. Children with leptin deficiency also
have abnormalities in T-cell number and function, resulting in frequent childhood
infections (Farooqi et al. 2002). Leptin deficient children and adults benefit from
replacement therapy with daily subcutaneous injections of human recombinant leptin
(Farooqi et al. 2002; Farooqi and O'Rahilly 2006). The major effects of leptin treatment
include normalization of hyperphagia and reduction of body weight and fat mass. It ha
been shown that the heterozygous relatives of leptin deficient subjects have partial leptin
deficiency, with significantly lower serum leptin levels than expected from their degree of
obesity (Farooqi et al. 2001).
4.3 Leptin receptor
In 1998 Clement and co-workers described a homozygous mutation in the LEPR gene in a
member of a consanguineous family. The mutation results in abnormal splicing of the
transcript. The mutant receptor lacks transmembrane and intracellul r domains but binds
leptin efficiently, thus leading to high circulating levels of leptin bound to the mutant non-
functional receptor. Recently, eight additional mutations of the LEPR gene were identified
(Farooqi et al. 2007a). Six of the probands were from consanguineous families and one
patient was compound heterozygous for two different mutations. Five of the mutations
were nonsense and four were missense mutations. The clinical phenotype associated with
LEPR deficiency is highly similar to the phenotype of leptin deficient paients, but
somewhat less severe. In these patients, serum leptin levels were not elevated compared to
equally obese subjects. Heterozygote carriers of LEPR mutations are characterized by
increased fat mass, but their body weight is not increased (Farooqi et al. 2007a).
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4.4 Pro-opiomelanocortin
Krude et al. (1998) described the first patients with congenital POMC deficiency. To date,
six children with homozygous or compound heterozygous mutations resulting in complete
loss of function of the POMC gene have been described (Farooqi et al. 2006). These
patients present with severe early-onset obesity and ACTH deficiency. The phenotype
includes pale skin and red hair color, due to the absence of α-MSH action on MC1R in
pigmentation. The pigmentation phenotype may vary according to the ethnic origin of the
patients, Caucasian subjects being more dependent on α-MSH in the synthesis of dark
eumelanin pigment (Farooqi et al. 2006). Heterozygous mutations in POMC may
contribute to inherited obesity (Krude et al. 2003b; Farooqi et al. 2006). A significantly
higher prevalence of obesity among heterozygous carriers of POMC null mutations has
been reported, indicating that POMC haploinsufficiency may be sufficient to predispose to
obesity (Krude et al. 2003b; Farooqi et al. 2006).
Furthermore, mutations in specific parts of the pre-prohormone POMC gene,
specifically affecting the melanocortin peptides, have been reported. Th  POMC R236G
mutation, disrupting a cleavage site between β-MSH and β-endorphin, results in a fusion
protein with an ability to bind to the MC4R, but with decreased ability to activate the
receptor (Challis et al. 2002). This mutation is suggested to increase the risk of obesity in
carriers. The POMC Y221C mutation affecting β-MSH was shown to be overrepresented
among obese subjects and the mutant peptide had impaired ability to bind to and activate
MC4R (Biebermann et al. 2006; Lee et al. 2006). In contrast to the loss of function
mutations described above, the carriers of these peptide mutations have no other clinical or
biochemical abnormalities besides obesity. These studies support the role of β-MSH as an
important agonist of MC4R in humans. In addition, several polymorphisms of the POMC
gene have been demonstrated to associate with common forms of obesity (Krude et al.
2003a; Rankinen et al. 2006).
4.5 Prohormone convertase 1
Three patients with congenital PC1 deficiency have been described (Jackson et al. 1997;
Jackson et al. 2003; Farooqi et al. 2007b). The first patient described presented with severe
early-onset obesity, hypogonadotropic hypogonadism, postprandial hypoglycemia and
hypocortisolism, due to impaired processing of POMC and proinsulin (Jackson et al.
1997). The patient was found to be a compound heterozygote for two mutations in the PC1
gene, G593R causing a failure of autocatalytic maturation of the peptide, an  a splice site
mutation resulting in exon skipping and a premature stop in the catalytic domain. The
second patient described was a compound heterozygote for two nonsense mutations,
E250X and 213delA, resulting in loss-of-function (Jackson et al. 2003). This patient
suffered from severe small intestinal absorptive dysfunction, in addition to the other
phenotypic characteristics described above. The small intestinal dysfunction seen in this
patient was due to abnormal processing of the prohormones progastrin and proglucag n in
the enteroendocrine cells (Jackson et al. 2003). In a recent study, a third patient with
congenital PC1 deficiency was described (Farooqi et al. 2007b). The patient was
homozygous for a missense mutation S307L, resulting in impaired catalytic activity of the
convertase (Farooqi et al. 2007b). The phenotypic characteristics of this pa ient included
obesity and diarrhea.
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4.6 Melanocortin-4 receptor
In humans, the role of the seven transmembrane G-protein coupled MC4R in the regulation
of body weight was highlighted in 1998, when two groups reported heterozygous
frameshift mutations in the MC4R gene as a cause of dominant, severe early-onset obesity
(Vaisse et al. 1998; Yeo et al. 1998). Subsequently and during the course of this study, a
number of studies have reported associations between early-onset morbid obes ty and
MC4R mutations in various ethnic groups (Gu et al. 1999; Hinney et al. 1999; Sina et al.
1999; Farooqi et al. 2000; Vaisse et al. 2000; Dubern et al. 2001; Mergen et al. 2001;
Hebebrand et al. 2002; Jacobson et al. 2002; Miraglia Del Giudice et al. 2002; Biebermann
et al. 2003; Donohoue et al. 2003; Farooqi et al. 2003; Hinney et al. 2003; Lubrano-
Berthelier et al. 2003b; Marti et al. 2003; Santini et al. 2004; Buono et al. 2005; Larsen et
al. 2005; Hinney et al. 2006; Lubrano-Berthelier et al. 2006; Rong et al. 2006; Wang et al.
2006; Ochoa et al. 2007). In different studies, the prevalence of MC4R mutations has
varied from 0.5% in obese adults (Larsen et al. 2005) to 6% in children with severe early-
onset obesity (Farooqi et al. 2003). The population prevalence of MC4R mutations is
estimated to be around 1-2.5% among people with a BMI greater than 30 kg/m2 (Larsen et
al. 2005) and thus MC4R deficiency represents the most common monogenic defect
causing human obesity so far reported (Vaisse et al. 2000; Farooqi and O'Rahilly 2006).
Theoretically, mutations in the MC4R promoter could also lead to obesity because of
reduced transcription of the gene. The human MC4R gene promoter was characterized and
investigated for possible abnormalities in 431 obese subjects by Lubrano-Berthelier et al.
(2003a), but no promoter mutations were identified.
4.7 Melanocortin-3 receptor
MC3R is a candidate gene that has been under extensive investigation for its p ssible role
in human obesity. The polymorphisms T6K and V81I have been identified in several
studies, but in the majority of cases they were not found to be associated with obesity (Li t
al. 2000; Hani et al. 2001; Wong et al. 2002; Feng et al. 2005). Three rare MC3R mutations
have been described to be associated with obesity (Lee et al. 2002; Rached et al. 2004; Tao
and Segaloff 2004; Lee et al. 2007).
4.8 Downstream targets of melanocortin signaling: SIM1, BDNF and TrkB
A few genes, including SIM1, BDNF and its receptor TrkB encoded by the gene NTRK2,
have been implicated as potential downstream targets of melanocorti signaling (Xu et al.
2003). A patient with severe early-onset obesity was reported to have a d  novo
translocation between the chromosomes 1p22.1 and 6q16.2 disrupting the SIM1 gene
(Holder et al. 2000). In studies with mice, it was shown that both Sim1 and Mc4r are
expressed in the PVN and it was hypothesized that SIM1 is involved in melanocortin
signaling (Michaud et al. 2001; Kublaoui et al. 2006). It was suggested that SIM1 regulates
feeding rather than energy expenditure, because in contrast to Mc4r and leptin deficient
mice, Sim1 mice are not characterized by decreased energy expenditure (Michaud et al.
2001).
The neurotrophin BDNF regulates the development, survival and differentiatio  of
neurons through its receptor TrkB (Xu et al. 2003). It has been shown that BDNF regulates
eating behavior (Kernie et al. 2000) and that its expression is reduced by fasting (Xu et al.
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2003). A mutation in the NTRK2 gene was identified in an 8-year-old boy with a complex
syndrome including severe obesity, impaired short term memory and developmental delay
(Yeo et al. 2004). The mutation identified in the NTRK2 gene has been suggested to impair
hypothalamic signaling processes (Yeo et al. 2004; Gray et al. 2007). Recently, a patient
with severe hyperphagia, morbid obesity, impaired cognitive function and memory, as well
as hyperactive behavior was described (Gray et al. 2006). The patient had a de novo
paracentric inversion in chromosome 11 disrupting the BDNF gene. The identification of
these two patients with rare mutations in BDNF and NTRK2 genes might facilitate the
understanding of mechanisms regulating the hypothalamic neuronal circuits underlying
regulation of energy balance (Farooqi and O'Rahilly 2006).
5 SYNDROMIC FORMS OF OBESITY
There are about 25 rare developmental syndromes that are characterized by obesity, such
as Prader-Willi syndrome, Bardet-Biedl syndrome, Alström syndrome, Cohen syndrome
and Borjeson-Forssman-Lehmann syndrome (for review, see Chung and Leibel 2005).
These obesity syndromes are usually associated with mental retardation, dysmorphic
features and organ-specific developmental abnormalities. In some cases the causative
genetic defects or chromosomal abnormalities have been identified, but in most cases the
molecular mechanisms underlying the syndrome are unknown. There is growing evidenc
of genetic heterogeneity for some of these conditions, with multiple genes producing
identical phenotypes, e.g. oligogenic inheritance in Bardet-Biedl syndrome (Chung and
Leibel 2005). Some of these obesity syndromes are associated with severe hyperphagia and
hypothalamic dysfunction. Therefore, the elucidation of the genetic basis of these disorders
could facilitate the identification of genes important for more comm n forms of obesity
(Chung and Leibel 2005).
The most frequent of these disorders is Prader-Willi syndrome, with an incidence
of one in 15,000-25,000 births (Chung and Leibel 2005). The syndrome is characterized by
obesity, hyperphagia, diminished fetal activity, mental retardation and hypogonadism. The
syndrome results from a loss of expression of paternal genes in the imprinted chromosomal
region 15q11-13. It was suggested that in Prader-Willi syndrome, the elevated production
of the gastric hormone ghrelin is responsible for increased appetite through POMC/CART
and NPY/AGRP hypothalamic circuits (Cummings et al. 2002). Bardet-Biedl syndrome is
characterized by early-onset obesity, rod-cone dystrophy, polydactyly, learning difficulties
and renal disease (Chung and Leibel 2005). The syndrome has been associated with a least
11 chromosomal loci, with several mutations identified at each locus and evidence of
complicated inheritance patterns of multiallelic transmission.
6 POLYGENIC, COMMON FORMS OF OBESITY
The present consensus maintains that common obesity is not caused by a defect in a single
gene, but results from the effects of the environment and several genes together (Bell et al.
2005). In addition to the environmental contribution, the polygenic nature of obesity makes
the search for obesity genes challenging. Each gene has a small effect on the phenotype
and the elucidation of gene-gene and gene-environment relationships in humans is difficult
(Mutch and Clement 2006a). Additionally, epigenetic mechanisms and imprinting have
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been suggested to have an impact on the regulation of genes involved in growth and
development (Waterland and Jirtle 2004).
The “thrifty gene” hypothesis was introduced in 1962 by James Neel. According to
this theory, some genes or genetic variants would have provided selective survival
advantage in times of famine and thus been maintained in the human genome during
evolution. In an obesity-promoting environment these genes do not provide advantage, bu
instead predispose to obesity and morbidity. Most westernized societies have an
environment that favors weight gain, because of the abundance of high-energy containing
foods and a lack of physical activity (Mutch and Clement 2006a).
A number of studies using both genome-wide linkage and candidate gene
approaches have identified a large number of genes predisposing to obesity. The latest
Human Obesity Gene Map: The 2005 Update (Rankinen et al. 2006) lists 253 QTLs for
obesity-related phenotypes identified in 61 genome-wide scans, 426 positive asociations
between obesity-related phenotypes and 127 different candidate genes. Table 3
summarizes some of the candidate genes frequently studied for association with obesity. A
complete list of genes associated with obesity can be found from the Obesity Gene Map
Database (http://obesitygene.pbrc.edu/).
Several of the genes of the leptin-melanocortin signaling system have been
implicated as candidates for common forms of obesity. For example, POMC and MC3R
have been extensively studied. Several linkage results to the genomic regions containing
the MC3R (Borecki et al. 1994; Lembertas et al. 1997; Stone et al. 2002) and POMC
(Hager et al. 1998; Comuzzie et al. 2001) genes have provided evidence for a role in
common obesity. POMC has been shown to be associated with leptin levels (Hixson et al.
1999; Miraglia del Giudice et al. 2001; Suviolahti et al. 2003b) and MC3R with several
obesity-associated traits (Boucher et al. 2002; Santoro et al. 2007).
The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) gene is an
interesting candidate gene not only for common forms of obesity, but also for insulin
resistance and type 2 diabetes. ENPP1 encodes a transmembrane glycoprotein that
interacts with the insulin receptor by inhibiting its tyrosine kinase ctivity and subsequent
signaling through the receptor (Maddux and Goldfine 2000). This in turn leads to
decreased insulin sensitivity. Several studies have demonstrated linkage between the
ENPP1 locus and obesity (Arya et al. 2002; Bell et al. 2004; Fox et al. 2004; Meyre et al.
2004). Further evidence for the role of ENPP1 is provided by studies showing association
between the ENPP1 K121Q variant and insulin resistance (Pizzuti et al. 1999; Gu et al.
2000; Frittitta et al. 2001; Abate et al. 2003), type 2 diabetes (Willer et al. 2007), as well as
obesity (Barroso et al. 2003; Meyre et al. 2005a; Böttcher et al. 2006; Wan et al. 2006).
The ENPP1 K121Q variant results in “gain of function” of the insulin receptor, the Q121
variant being a stronger inhibitor of the receptor (Costanzo et al. 2001). There are also
studies which failed to find evidence for association between ENPP1 and obesity, insulin
resistance or type 2 diabetes (Chen et al. 2006; Gouni-Berthold et a. 2006; Lyon et al.
2006; Matsuoka et al. 2006; Weedon et al. 2006; Meyre et al. 2007). However, meta-
analyses show that although the results are somewhat controversial, individuals carrying
the Q121 variant have a higher risk of type 2 diabetes (Abate et al. 2005; Bacci et al. 2005;
Grarup et al. 2006).
In 2006 Herbert et al. reported an association between adult and childhood obesity
and a common SNP, rs7566605, located near the INSIG2 gene (Herbert et al. 2006). The
study sample consisted of 9881 adults and children, combined from case-control, family
and general population cohorts from various ethnic groups. The association was found
through a genome-wide association study of 86604 SNPs, under a recessive model. Other
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studies investigating the role of the INSIG2 SNP rs7566605 have been performed, but the
results have not been confirmed (Dina et al. 2007; Loos et al. 2007; Rosskopf et al. 2007).
Table 3. Examples of candidate genes which have been associted with obesity-related phenotypes in
multiple studies.
Gene Chromosome Phenotype References
ADIPOQ Adiponectin 3q27 Weight, waist circumference
BMI, abdominal diameter
BMI, waist circumference
Menzaghi et al. 2002
Ukkola et al. 2003







Oppert et al. 1995
Garenc et al. 2002
Ukkola et al. 2000
ADRB2 Adrenergic receptor
β2




Meirhaeghe et al. 2000
Pereira et al. 2003






Hao et al. 2004
Oksanen et al. 1996
Thomas et al. 2000
AGRP Agouti related
protein
16q22 BMI, body fat mass and
percentage
BMI, weight, body fat mass
and percentage
Argyropoulos et al. 2002
Marks et al. 2004
GAD2 Glutamate
decarboxylase 2
10p12 Morbid obesity, eating
behavior
Obesity, birth weight
Boutin et al. 2003
Meyre et al. 2005b
GHRL Ghrelin 3p26-p25 BMI
Obesity
Korbonits et al. 2002
Ukkola et al. 2001a
LEP Leptin 7q31.3 Decrease in body weight
Leptin, obesity
BMI
Oksanen et al. 1997
Jiang et al. 2004
Le Stunff et al. 2000
LEPR Leptin receptor 1p31 BMI, fat mass
Fat mass, lean mass
BMI
Changnon et al. 2000
Liu et al. 2004
Ross et al. 2004
NPY Neuropeptide Y 7p15.1 BMI, WHR
BMI
Body weight at birth
Bray et al. 2000
Ding et al. 2005







Kim et al. 2004
Meirhaeghe et al. 2005






Xq24 Obesity, eating behavior
Obesity
Durand et al. 2004






Heilbronn et al. 2000
Kim et al. 2005





Evans et al. 2001
Marti et al. 2004
UCP3 Uncoupling protein
3




Damcott et al. 2004
Ukkola et al. 2001b
A new candidate gene for polygenic obesity, FTO, was identified in a recent study
(Frayling et al. 2007). The FTO gene, having an effect on BMI, was originally identified in
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a genome-wide association study searching for type 2 diabetes susceptibility genes. The
association between BMI and a common gene variant (rs9939609, minor allele frequ ncy
0.39) was replicated in several population-based cohorts. Altogether, nearly 40,000
participants were studied and the SNP rs9939609 was shown to be significantly associated
with BMI in children and adults. The SNP is located within the first intron of the FTO
gene, but the genetic and functional mechanisms underlying this association are still
unclear. The FTO is a gene of unknown function and was cloned as a result of the
identification of a mutant mouse model, fused toe (Ft) Anselme et al. 2007). This gene
represents the first example of a common genetic variant predisosing to obesity at the
general population level (Frayling et al. 2007).
7 AN APPROACH TO A MOLECULAR GENETIC EVALUATION OF A
MORBIDLY OBESE PATIENT: A CLINICAL PERSPECTIVE
The number of loci and genes associated with obesity is constantly increasi g and depicts a
complex view of the field of obesity genetics. Although several genes underlyi g
monogenic and syndromic obesity have been identified, the genetic studies have mainly
produced information about a large number of susceptibility genes and the findings have
not always been replicated by others (Mutch and Clement 2006a). In contrast to monogenic
obesity, an individual polymorphism in a single susceptibility gene may not be sufficient to
cause the phenotype, but rather represents a risk factor among other gen tic and
environmental components predisposing to obesity (Mutch and Clement 2006a). In the
case of an obese patient, combining the genetic information with informati n about other
risk factors is a challenge for the physicians (Mutch and Clement 2006a). At the present
time no systematic patient-oriented screening of gene variants predi posing for common
obesity is possible.
In cases of severe early-onset obesity, in the absence of evidence for syndromic
obesity, it is reasonable to investigate most of the genes encoding the leptin-melanocortin
signaling system. MC4R is a plausible candidate worth studying, because MC4R deficiency
represents the most common monogenic defect causing human obesity. The identificatio
of these monogenic disorders have helped to destigmatize human obesity and allowe it to
be seen as a medical condition rather than a moral failure of the patient (Farooqi and
O'Rahilly 2006).
It is obvious that monogenic cases of obesity are rare. Potential therapies for
affected individuals are available, as successfully demonstrated in the case of leptin
deficiency (Farooqi et al. 1999). However, leptin therapy is of limited significance for
public health care, as patients suffering from common obesity do not benefit from
presently available agents affecting the leptin-melanocortin system. Despite intensive
efforts to develop potent and selective ligands for melanocortin receptors, no specific
therapies are today available for MC4R or POMC mutation carriers (Nargund et al. 2006).
In POMC deficient children a three-month trial with an MC4R agonist was inefficient in
affecting food intake or weight (Krude et al. 2003b). In contrast, these patients might
benefit from the development of new small-molecule MC4R agonists. For example,
analogs of β-MSH have been shown to have beneficial effects in vitro and in vivo in obese
mice (Hsiung et al. 2005; Farooqi and O'Rahilly 2006). The heterozygous carriers of
MC4R mutations may show favorable responses to pharmacotherapy with these new




The aim of the present thesis study was to investigate if severe arly-onset obesity in children
and morbid obesity in adults can be explained by genetic variation in the melanocortin
signaling pathway, with particular focus on the melanocortin receptors 3 and 4.
The specific aims were to:
1. Investigate the occurrence of monogenic forms of obesity caused by mutations in selected
candidate genes in two cohorts, i.e. morbidly obese adults and children with severe early-
onset obesity.
2. Identify common genetic variants, and to study previously known polymorphisms in
obesity candidate genes with potential phenotypic effects leading to polygenic forms of
obesity.
3. Perform in vitro cell studies in order to learn about structure-activity relationships of
mutant MC4R.
4. Explore whether the proximal promoter regions of the MC3R and MC4R genes contain
mutations or variations that are associated with obesity and whether these alterations
could affect the binding of transcription factors.






1.1 Morbidly obese adults
The cohort of morbidly obese adults consisted of 252 subjects (BMI ≥ 40 kg/m2). The
morbidly obese individuals were recruited from the obesity clinic at the Department of
Endocrinology, Helsinki University Central Hospital during years 1989-1995 (Oksanen et al.
1996). The cohort included 182 females and 70 males and their mean age (± SD) was 48.6 (±
9.9) years. A detailed history including data on medical history and drug treatment, as well as
history of weight development, was assessed by a questionnaire. The subjects were weighed
and their height and blood pressure were measured. Blood samples for DNA extraction and
serum leptin, lipid, glucose and insulin were drawn after a twelve hour fast.
In study I, 48 subjects were examined for mutations in the MC3R gene, and the
variants detected were genotyped in the entire cohort. To date, all subjects have been
examined for mutations in the MC3R gene (partly unpublished data). In study II, all 252
subjects were examined for mutations in the MC4R gene. In study IV, 246 DNA samples
were available for haplotype analysis of the MC2R, MC3R, MC4R, MC5R, POMC and
ENPP1 genes.
1.2 Children with severe early-onset obesity
Since year 2001, children with severe early-onset obesity were recruited from the Helsinki
University Hospital for Children and Adolescents. The original admission criteria were a
relative weight for height ratio ≥ +60% or age-specific relative BMI greater than the 98th
percentile value before age of ten years. At inclusion, the patients were carefully examined,
weight and height as well as WHR and blood pressure were recorded. Blood samples were
drawn for DNA extraction and serum lipid, glucose and hormone measurements (thyroid-
stimulating hormone, thyroxine, luteinizing hormone, follicle stimulating hormone, estradiol,
testosterone etc.) after a twelve hour fast. Weight and length chart dat  from birth onwards
were available for all children.
Fifty-six children (29 females and 27 males) were included in study II and examined
for mutations in the MC4R gene. In study III, the number of children examined for mutations
in MC4R was extended to 152 (66 females and 86 males). These 152 patients have also b en
examined for mutations in the MC3R and POMC genes (unpublished data). The entire cohort
consisted of 199 children (90 females and 109 males), with a mean age (± SD) of 12.3 (± 3.9)
years. All the children have been examined for mutations in the MC4R gene (partly
unpublished data).
1.3 Background population
In studies I and II, DNA samples from 321 healthy blood donors (153 females and 159 males)
served as controls for the estimation of allele frequencies in the background population. The
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samples were obtained from the Finnish Red Cross Blood Transfusion Service. No data on
BMI were available from these individuals.
1.4 Lean subjects
In studies III and IV, lean subjects (BMI 20-25 kg/m2) from the national FINRISK97 cohort
(Vartiainen et al. 2000) served as controls. The lean subjects were sel cted from the same
geographical area as the adult obese subjects. In study III 447 subject (374 females and 73
males, mean age ± SD, 52.1 ± 8.4 years), and in study IV 481 subjects (406 females and 75
males, mean age ± SD, 52.3 ± 8.3 years), served as controls.
1.5 Ethical aspects
The studies were approved by the local Ethics Review Committee of the Department of
Medicine, University of Helsinki and carried out according to the principles of the
Declaration of Helsinki. Written informed consent was obtained from all participants or in the
case of minors, from their guardians.
2 MOLECULAR GENETIC STUDIES
2.1 DNA extraction (studies I-IV)
Genomic DNA was extracted from peripheral blood lymphocytes either by a standard phenol-
chloroform method (Blin and Stafford 1976), or by a salting out method with the Pur gene
DNA whole blood purification kit (Gentra, Minneapolis, MN, USA).
2.2 Polymerase Chain Reaction (studies I-IV)
Genomic DNA was amplified by use of Polymerase Chain Reaction (PCR) (Mullis et al.
1986). PCR was performed in varying conditions. In most cases, Amplitaq Gold DNA
polymerase (Applied Biosystems, Foster City, CA, USA) was used. Intronic primers were
designed in order to cover entire coding regions of the genes studied. If possible, promoter
regions and untranslated regions (UTR) of the genes were included.
2.3 Denaturing High Performance Liquid Chromatography (studies II, III)
Mutations and polymorphisms in the MC3R, MC4R and NHLH2 genes were searched by use
of denaturing high performance liquid chromatography (dHPLC) (Donohoe 2005). DHPLC
was carried out on a WAVE nucleic acid fragment analysis system HSM 3500A with a
DNASep column (Transgenomic, Omaha, NE, USA). Optimal melting curves, column
temperatures and eluent concentrations were calculated, separately for ach PCR amplified
fragment, with Wavemaker 4.1 software (Transgenomic). PCR fragments showing divergent
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curve profiles in the chromatograms, indicating the presence of a heteroduplex fragment, were
subsequently sequenced to identify the nucleotide substitution.
2.4 Sequencing (studies I-III)
The PCR products were purified enzymatically by use of shrimp alkaline phosphatase and
exonuclease I. Sequencing reactions were performed using BigDye (Applied Biosystems)
chemistry, which is based on the incorporation of di-deoxynucleotides terminating the
elongation reaction (Sanger et al. 1977). The reactions were separated with an automated
sequencer, ABI 377 or 3730 (Applied Biosystems), and the sequences were analyzed with
Sequencher software (Gene Codes, Ann Arbor, MI, USA).
2.5 Specific detection methods for DNA alterations (studies I-III)
When mutations or polymorphisms were detected, a specific detection method was set up for
each DNA alteration (Table 4). DNA samples available from relatives and control individuals
were genotyped. Most of the methods set up were based on restriction enzyme digestion and
electrophoretic separation of the cleavage products, either on an agarose or a polyacrylamide
gel. In most cases a restriction enzyme cleavage site was naturally present at the site of the
DNA alteration. In some cases artificial restriction enzyme cleavage sites were generated by
primer-induced restriction analysis (Kumar and Dunn 1989). The restriction enzymes used
were purchased from New England Biolabs (NEB, Beverly, MA, USA) and Fermentas
(Burlington, Ontario, Canada). The MC3R L249V variant was detected by dHPLC and the
POMC insertion polymorphism 73/74insSSG by heteroduplex analysis (White et al. 1992).
Table 4. Specific detection methods for DNA alterations detected.
Gene DNA alteration Method
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2.6 SNP genotyping by SEQUENOM massARRAY (study IV)
To confirm that the SNPs with no prior frequency information were polymorphic (had a
frequency over 10%), 15 control individuals and a DNA-pool of 130 control samples were
genotyped. In order to confirm Mendelian inheritance, 57 nuclear families including a father,
mother and child were genotyped. Reproducibility of genotype data was guaranteed by
genotyping 2% of all samples in duplicates. SNPs were excluded from fu ther genotyping if
they were in complete LD with an adjacent SNP. Assay validity creria for acceptance of
SNPs for genotyping were: 1) no discordant results in duplicates, 2) allele distributions in
Hardy-Weinberg equilibrium, 3) no Mendelian errors in the nuclear families and 4)
genotyping success rate > 90%.
SNPs were genotyped using the homogenous MassEXTEND® assay on the
MassARRAY® system (SEQUENOM Inc., San Diego, CA, USA) according to the
manufacturer’s instructions (Jurinke et al. 2002). The method is based on allele-specific
primer extension, resulting in extension products each having a unique molar ass. The
extension products having distinct masses can be detected by use of a matrix assisted laser
desorption/ionization time-of-flight mass spectrometry.
2.7 Bioinformatics and computational biology (studies I-IV)
Several internet search tools, databases and free software, as w ll as commercial programs
were utilized during this study. Particularly valuable were the Obesity Gene Map Database
(http://obesitygene.pbrc.edu/), National Center for Biotechnology Information NCBI
(http://www.ncbi.nlm.nih.gov/) and UCSC Genome Bioinformatics (http://genome.ucsc.edu/)
sites. In all studies, PCR primers were designed with the Primer3 program (Rozen and
Skaletsky 2000). Webcutter 2.0 (http://www.firstmarket.com/cutter/cut2.html) and
RestrictionMapper (http://www.restrictionmapper.org/index.htm) programs were used when
setting up the specific detection methods for DNA alterations. DNA alterations located in
non-coding regions were analyzed by MatInspector (Quandt et al. 1995), TFSearch
(Heinemeyer et al. 1998), TESS (Schug and Overton 1997), ConSite (Sandelin et al. 2004)
and Con Real (Berezikov et al. 2004) programs. In study IV, human and mouse sequences
were compared using Pipmaker (Schwartz et al. 2000) and Vista (Frazer et al. 2004) software.
3 STATISTICAL METHODS (studies I-IV)
Statistical analyses were mainly performed with NCSS 2000 software (NCSS, Kaysville,
Utah, USA). Differences in allele and genotype frequencies between groups were tested by
chi-square or Fisher’s exact tests, where appropriate. In study I, Mann-Whitney rank-sum test
was used to analyze differences between group means of metabolic parameters. In study IV,
Genepop v3.4 Option 2 software (Raymond and Rousset 1995) was used to test the LD
between adjacent SNPs. Both D’ and r2 values were calculated in order to test pairwise LD
between the SNPs. Haplotype structure and frequencies were estimat d using Haploview
software (Barrett et al. 2005). The association of each SNP genotype with obesity and
diabetes was assessed using logistic regression analysis, by adjusting for age and sex. A type
1 error rate of 0.1 for multiple testing was controlled for by using the false discovery rate




4.1 Preparation of plasmid constructs (studies II, III)
Site-directed mutagenesis and cloning techniques were utilized in creating constructs for the
functional analyses. In study II, MC4R mutations T112M, S127L, M200V (unpublished) and
I226T were introduced into two constructs; a human MC4R cloned in pcDNA3 (Invitrogen,
Carlsbad, CA, USA) and a HA-tagged MC4R green fluorescent protein fusion protein (HA-
MC4R-GFP) encoded in pEGFP-N1 (BD Biosciences Clontech, Palo Alto, CA, USA). The
constructs were kindly provided by Dr. J.S. Flier (Shinyama et al. 2003). The mutations were
incorporated with a QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA).
For study III, human NHLH2 cloned in pBluescript II (Stratagene) was kindly
provided by Dr. I.R. Kirsch (Lipkowitz et al. 1992). For gel shift assays, n EcoRI (NEB) and
XbaI (NEB) restricted complementary DNA fragment of NHLH2 was sub-cloned by ligation
in-frame to pFLAG-CMV2 (Sigma-Aldrich, Inc., St. Louis, MO, USA). For reporter gene
experiments the Mc4rwt and Mc4rdelGC constructs were created by amplifying the MC4R
minimal promoter region (Mc4r-130/+10, according to (Lubrano-Berthelier t al. 2003a) by
PCR. By amplifying heterozygous patient DNA, both mutant and wild-type (wt) promoter
constructs were produced simultaneously. The PCR primers contained NheI (NEB) and XhoI
(NEB) restriction sites enabling the ligation of the PCR fragments to pGL3-basic (Promega,
Madison, WI, USA). The integrity of all constructs was verified by sequencing.
4.2 Cell culture and transfection: in vitro expression studies (studies II, III)
The functional properties of mutant MC4Rs were studied in 293T cells(American Type
Culture Collection, ATCC, Manassas, VA, USA). Nuclear cell extracts containing NHLH2
protein was prepared in COS-1 cells (ATCC) and the MC4R promoter was studied in HeLa
(ATCC), COS-1 and LβT2 cells (provided by Dr. P.L. Mellon) (Thomas et al. 1996). The
293T cells were maintained in Dulbecco’s Modified Eagle Medium, high glucose,
supplemented with 10% (vol/vol) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin
and 100 µg/ml streptomycin, at 37ºC in a humidified atmosphere containing 5% CO2. The cell
culture conditions were similar for all cells, but media concentrations were adjusted according
to the requirements of each cell type.
MC4R signaling was studied by transiently transfecting 293T cells with t or mutant
MC4R and a cAMP responsive thyrotropin releasing hormone (TRH) luciferase eporter
(TRH-Luc) (Harris et al. 2001) (Figure 2A). Transfections were performed with
Lipofectamine Reagent (Invitrogen) in OPTI-MEM I Reduced Serum Medium (Invitrogen).
After transfection and overnight incubation cells were stimulated with increasing amounts of
the MC4R agonists α-MSH (Sigma-Aldrich), β-MSH (Phoenix Pharmaceuticals, Belmont,
CA, USA) or γ1-MSH (Phoenix Pharmaceuticals) and incubated for 5 h at 37°C, 5% CO2. To
evaluate the effect of the MC4R antagonist AGRP (83-132) (Phoenix Pharmaceuticals) on the
mutant receptors, cells were pretreated with increasing concentratio s of AGRP for 30 min
and incubated for 5 h in a constant 100 nM α- SH concentration. The luciferase activity was
measured with an EG&G Berthold LB 9501 Luminometer (Berthold Technologies, Bad
Wilbad, Germany) (Bjørbæk et al. 1998). A β-galactosidase expression vector under control
of a CMV promoter was included in all transfections as an internal control. All values were
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normalized for transfection efficiency by determination of ß-galactosidase activity with the
Galacto-Light kit (Applied Biosystems).
The functional properties of variant receptor M200V was studied in 293H cells
(ATCC) in a similar way as described above. FuGENE-6 (Roche Molecular Biochemicals,
Mannheim, Germany) was used as transfection reagent and luciferase activity was measured
with the Dual-Luciferase Reporter Assay System (Promega). The system allows the
determination of firefly and Renilla luciferase activities from the same cell lysates.
Normalization for transfection efficiency was performed by determination of Renilla
luciferase activity of the internal pRL- control vector (Promega).
In study III, nuclear extracts of NHLH2 were prepared by transfecting COS-1 cells
with the NHLH2 construct by FuGENE-6 Transfection Reagent (Roche Molecular
Biochemicals). Cells were collected 48 h after transfection, washed once with phosphate
buffered saline (PBS) and lysed. In the MC4R promoter assays (Figure 2B) HeLa, COS-1 or
LβT2 cells (Windle et al. 1990) were transfected with luciferase reporter Mc4rwt or
Mc4rdelGC. The cells were lysed 48 h after transfection with report r lysis buffer (Promega)
and the luciferase activity was determined with reagents from Pro ega and a Luminoscan
Ascent reader (Thermo LabSystems, Beverly, MA, USA). An internal control vector pCMVβ
(Clontech, Palo Alto, CA, USA) was included in all transfections and the values were
normalized for transfection efficiency by enzymatic determination of β-galactosidase activity
(Kotaja et al. 2002).
Figure 2. Principles of the in vitro expression methods used. A) 293T or 293H cells were transiently transfected
with wt or mutant MC4R and a cAMP responsive TRH-Luc reporter construct. The cells were stimulated with
MC4R agonists α-MSH, β-MSH or γ1-MSH. The stimulation of MC4R leads to the increase of intracellular
cAMP levels. Cyclic-AMP binds to the TRH promoter and turns on the luciferase activity of the reporter
construct, which can be determined luminometrically. Binding of the MC4R agonist AGRP was studied by
measuring luciferase activity of α-MSH stimulated cells that were pretreated with AGRP. B) The -493delGC
deletion in the MC4R promoter was studied by transiently transfecting HeLa, COS-1 or LβT2 cells with
luciferase reporter constructs containing wt (Mc4rwt) or mutant (Mc4rdelGC) promoters. The luciferase ctivity
produced by the Mc4rwt or Mc4rdelGC promoter was determined.
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4.3 Western blotting (studies II, III)
To ensure that the transfection efficiency was adequate for the following experiments, the wt
and mutant MC4R proteins were detected by standard Western blotting procedu es. In study
II, a monoclonal anti-HA antibody (Roche Molecular Biochemicals) recognizing the HA-tag
included in the MC4R constructs was used. In study III, the expression efficiency of
transfected NHLH2 was detected using a monoclonal anti-FLAG antibody (Roche Molecular
Biochemicals).
4.4 Immunofluorescence and Enzyme Linked Immunosorbent Assay (study II)
To evaluate whether the MC4R mutant receptors were functionally impaired due to
intracellular retention, immunofluorescence and enzyme linked immunosorbent assay
(ELISA) experiments were performed in 293T or 293H cells to detect HA-MC4R-GFP at the
cell surface. Cells were plated on Poly-D-lysine (Sigma-Aldrich) oated Lab-Tek Chamber
Slides (Nalge Nunc International, Naperville, IL, USA) or on 24-well plates and transfected
with mutant and wt vectors. For immunofluorescence cells were washed once with cold PBS,
fixed with 3% paraformaldehyde in PBS and mounted with VECTASHIELD Mounting
Medium with DAPI (4',6-diamidino-2-phenylindole) (Vector Laboratories, Burlingame, CA,
USA) or Calbiochem MOWIOL 4-88 Reagent (Merck KgaA, Darmstadt, Germany). Cells
were visualized on a fluorescence microscope and images were taken with a digital camera.
ELISA was performed as described by Shinyama et al. (2003). Briefly, monoclonal high
affinity anti-HA-peroxidase antibody (Roche Molecular Biochemicals) nd POD substrate
(Roche Molecular Biochemicals) were used in the peroxidase-mediated ELISA and the
absorbance was measured at 450 nm.
4.5 Electrophoretic Mobility Shift Assay (studies I, III)
The binding of proteins to specific regions in MC3R and MC4R promoters were studied by
electrophoretic mobility shift assays (EMSA). Nuclear proteins for gel shifts with the MC3R
promoter were prepared from cell lines expressing GATA-4 and GATA-6 (MSC-1, mouse
Sertoli), GATA-3 (Jurkat, T-cell lymphoma) and no known GATA proteins (NIH 3T3,
fibroblast). Extracts of cells trasfected with NHLH2 were used for experiments with the
MC4R promoter. All cell extracts were prepared as described by Andrews and Faller (1991).
Probes were annealed and labeled with [γ-32P]ATP as described in detail in studies I and III.
In study I, binding reactions were performed as described by Martelin e al. (2000). GATA
antibodies for supershift experiments were purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). In study III, binding reactions were performed in binding buffer (10
mM Tris-HCl pH 8.0, 40 mM KCl, 0.1% Nonidet P-40, 6% glycerol, 1 mM dithiothrei ol,
1:100 protease inhibitor cocktail). The labeled probe was added to the reaction and incubated
at 4°C for 30 minutes. In both studies the samples were separated on 4% polyacrylamide gels




1 GENETIC VARIATIONS IDENTIFIED IN FINNISH OBESE PATIENTS
1.1 The melanocortin-3 receptor gene
In study I, 48 morbidly obese adults were screened for mutations in the MC3R gene by
sequencing. The previously described common missense mutations in the coding regio , T6L
and V81I, and a 5’UTR variant -239A>G were detected in the MC3R gene (Li et al. 2000;
Hani et al. 2001). Additionally, four previously unknown variants -939G>C, -911G>A,
-803T>C and -373G>T were detected in the 5’UTR.
Allele frequencies of genetic variants -239A>G, T6L and V81I were detrmined in the
entire cohort of morbidly obese subjects and in a background population sample of healthy
blood donors (Table 5). Allele frequencies did not differ significantly between the groups
studied. The T6L and V81I variants were co-inherited in all but 3 cases, indicating a high
level of LD. Individuals carrying the wt alleles (T6/V81) had lower insulin-glucose ratio (3.1
± 0.2 vs. 4.1 ± 0.4, p<0.05) and lower leptin (ng/ml) levels (38.5 ± 1.5 vs. 46.4 ± 3.6, p<0.05)
compared to those carrying the heterozygous and homozygous variant alleles.
To date, the entire cohort of morbidly obese adults (n=252) and 152 children with
severe early-onset obesity have been investigated for mutations in the MC3R gene. In addition
to the variants described above, a silent nucleotide substitution 354G>C (A118A), a missense
mutation L249V and a nucleotide substitution 1091G>A in the 3’UTR were detected among
morbidly obese adults. The missense mutation L249V was not detected in the background
population (n=312). Allele frequencies of variants -239A>G, T6L and V81I were also
determined in the cohort of children with severe early-onset obesity (Table 5). Furthermore,
previously unknown variants -335G>A, -135insCT and 327G>A (P109P) were detected
among patients with severe early-onset obesity.
Table 5. Minor allele frequencies of MC3R variants in morbidly obese adults, children with severe early-onset





Children with severe early-onset
obesity (n=152)
Background population (n=312)
-239A>G 0.11 0.10 0.13
T6L 0.09 0.14 0.11
V81I 0.08 0.12 0.10
1.2 The melanocortin-4 receptor gene
A total of 252 morbidly obese adults and 199 children with early-onset obesity were
investigated for mutations in the MC4R gene by dHPLC and direct sequencing (studies II, III
and unpublished data). Several heterozygous mutations and polymorphisms were detected in
the MC4R gene (Figure 3 and Table 6). In studies II and III, the missense mutations V103I
and S127L, a deletion -439delGC in the putative promoter region and a nucleotide
substitution 1059C>T in the 3’UTR of MC4R were identified among severely obese children.
Among adult morbidly obese patients, the variants V103I, T112M, I226T, and I251L were
detected. In addition, four common polymorphisms (-1042C>T, -1005C>T, -896C>T and
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-719G>A) were found in the 5’ flanking region of MC4R in all cohorts studied. At a later time
point, the number of patients in the cohort of children with severe early-onset obesity was
extended to 199 (unpublished data). The following genetic variants were detecte  among the
newly recruited patients: nucleotide substitutions -483C>T and -178A>C in the 5’UTR, a
deletion 308delT and missense variants V103I, T112M, S127L, M200V and P229H in the
coding region of the MC4R gene. All mutations and polymorphisms in the MC4R gene were
detected in heterozygous form.
Figure 3. Schematic drawing presenting the location of mutations and polymorphisms detected in the MC4R
gene. A) Genetic variants in the coding region of the MC4R. B) Variants located in the promoter region, 5’UTR
and 3’UTR of the MC4R gene.
Table 6. MC4R mutations and polymorphisms identified in heterozygous form in children with early-onset
obesity and morbidly obese adults.
MC4R variant Children with severe early-





-483C>T 1 0 ND
-439delGC 2 0 1a
-178A>C 1 0 ND
308delT 1 0 0
V103I 3 1 9
T112M 2 3 0
S127L 2 0 0
M200V 1 0 0
I226T 0 1 3
I251L 0 1 8
P299H 1 0 0
1059C>T 1 0 ND
ND, not determined. aThe deletion was not present in 447 lean controls.
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Three of the genetic variants identified can be regarded as mutations that affect the
function of the receptor (308delT, S127L, P299H). The deletion -439delGC in the MC4R
promoter affects a basic helix-loop-helix (bHLH)-binding sequence ad might have an impact
on the transcriptional activity of the gene. The other genetic variants identified are proposed
to be polymorphisms with no detectable effect on the activity of the gen or on the function of
the receptor.
1.2.1 Mutations in the coding region of MC4R
A novel deletion, 308delT, was identified in a 13.3-year-old girl (unpublished data). The 1-
basepair deletion at nucleotide position 308 causes a frameshift at codon 103, and introduces a
stretch of four new amino acids (Ala-Ser-Pro-Tyr) and a premature stop at codon 107. The
308delT index patient had early-onset obesity and early-onset type 2 diabetes. Her abnormal
weight-gain began before the age of one year (Figure 5A) and type 2 diabetes was diagnosed
at the age of 13 years. The patient’s glycosylated hemoglobin was 7.3% (normal range 4-6%)
and she was negative for autoantibodies associated with type 1 diabetes. The index patient’s
mother was shown to be a carrier of the 308delT mutation (Figure 4). The mother’s BMI was
> 25 kg/m2 and she was severely obese in childhood. The index patient had familial
predisposition for type 2 diabetes, as her father, paternal grandfather nd maternal
grandmother, were affected by the disease.
Figure 4. Pedigrees of families with MC4R mutations. The index patients are indicated by arrows. Modified from
figure 1A, study II.
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Figure 5. Charts presenting the weight development of index patients with MC4R mutations. A) 308delT, B)
S127L index patient A, C) S127L index patient B, D) P299H. Modified from figure 1B, study II.
A missense mutation P299H was identified in a 9.3-year-old boy (unpublished data).
The mutation has been described and the functional properties investigated previously
(Lubrano-Berthelier et al. 2003b). Lubrano-Berthelier and co-workers demonstrated that the
P299H mutation leads to intracellular retention of the receptor. The index patient’s abnormal
weight gain began in the second year of life (Figure 5D). The P299H mutation was also
detected in the index patient’s obese father, the father’s lean brother and the overweight
paternal grandfather (Figure 4).
The S127L mutation was first detected in a 14.8-year-old boy (study II) and later the
same mutation was identified in a 12.5-year old girl (unpublished data). Both carriers of the
S127L mutations were also carriers of the MC4R polymorphism V103I. The receptor is
transported normally to the cell membrane, but signaling through the mutated receptor is
impaired (study II and Lubrano-Berthelier et al. 2003b). Index patient A’s abnormal weight
gain began in the second year of life (Figure 5B). He had normal glucose tolerance, but an
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oral glucose tolerance test (OGTT) revealed marked hyperinsulinemia (detailed information
in study II) and he presented with acanthosis nigricans in the neck and axillae indicating
insulin resistance. In family A, only the proband’s moderately obese fath r proved to be
positive for the S127L mutation, which could not be found in the grandparents (Figure 4).
Index patient B started abnormally gaining weight at the age of five years (Figure 5C). In
family B, the index patient’s lean brother, morbidly obese father and overweight paternal
grandmother were shown to be carriers of the S127L mutation (Figure 4).
Table 7 presents the clinical characteristics of MC4R mutation carriers.
Table 7. Clinical features and hormone levels in the six index patients carrying MC4R mutations.












Sex Female Male Male Female Female Male
Age, years 13.3 9.3 14.8 12.5 13.8 10.1















BMI, kg/m2 45.9 39.2 36.7 33.6 33.5 31.2
fP-Glucose, mmol/l a 7.2 5.0 4.7 5.8 5.6 4.9
fS-Insulin, mU/l b 39.0 35.6 33.0 22.8 14.0 38.0




144/88 134/70 123/71 140/70 136/79 112/65
fP-Cholesterol,
mmol/l c
5.3 3.8 4.2 4.2 5.0 2.7
fP-Chol-HDL,
mmol/l d
1.0 1.03 1.31 1.05 1.11 0.75
fP-Chol-LDL,
mmol/l e
2.95 2.38 2.31 2.52 3.26 1.59
f-Triglycerides,
mmol/l f
2.95 0.86 1.13 1.39 1.36 1.8
P-ALAT, U/l g 163 15 64 19 18 227
P-Urate, µmol/l h 523 195 505 310 292 396
S-TSH, mU/l i 2.20 1.99 1.28 3.93 3.3 1.7
S-T4-free, pmol/l j 14.0 15.0 14.0 15.0 11.0 14.0
S-Estradiol, nmol/l 0.09 - - 0.06 0.06 -
S-LH, IU/l 5.4 <0.1 0.8 2.2 1.5 <0.1
S-FSH, IU/l 5.8 0.1 1.2 6.2 3.6 0.3
Testosterone, nmol/l - 0.3 7.0 - - 0.1
Abbreviations used in the table: SDS, standard deviation score; fP, fasting plasma; fS, fasting serum; S, serum;
HDL, high density lipoprotein; LDL, low density lipo rotein; f, fasting; ALAT, alanine aminotransferase; TSH,
thyroid-stimulating hormone; T4, thyroxine; LH, luteinizing hormone, FSH, follicle stimulating hormone.
Normal range: a 3.8-7 nmol/l, b 2.3-26 mU/l, c <5mol/l, d  0.93-1.94 mol/l, e 1.6-3.6 mol/l, f children 13-months
to 9-years 0.31-1.46 mol/l, children 10-13-years 0.27-1.64 mol/l, boys 14-15-years 0.38-1.86 mol/l, g <40 U/l, h
120-330 µmol/l, i 0.4-5 mU/l and j girls 11-15-years 10-19 pmol/l, boys 6-10-years 10-22 pmol/l, boys 11-15-
years 12-20 pmol/l.
1.2.2 A deletion in the MC4R promoter, -439delGC
In studies II and III, the deletion -439delGC was identified in two unrelated children with
severe early-onset obesity. The presence of the -439delGC deletion was i vestigated in 454




The mutation was first found in a 13.8-year-old girl with a BMI of 33.5 kg/m2 and
later the same mutation was identified in a 10.1-year-old boy with a BMI of 31.2 kg/m2. Both
mutation carriers had abnormal weight gain from the age of four years onwards. Detailed
information about the weight development of these children can be found in study III. In
family A, the index patient’s 35-year-old half-sister was a carrier of the -439delGC mutation.
She had a history of childhood obesity and is currently obese (BMI 31.9 kg/m2). In family B,
the index patient’s 11.8-year-old obese brother (BMI 27.6 kg/m2), lean father (current BMI
23.1 kg/m2, overweight in infancy) and the father’s lean sister (current BMI 23.7 kg/m2,
overweight as a child until reaching puberty) were carriers of the mutation. (Pedigrees of the
families are shown in study III).
1.3 The nescient helix loop helix 2 gene
In study III, the possible role of transcription factor NHLH2 in obesity was investigated by
screening the gene for mutations in 152 subjects with severe early-onset obesity. No
mutations were detected in the NHLH2 gene. However, one silent nucleotide substitution
96C>T (L32L) was found in two children with severe early-onset obesity.
1.4 The pro-opiomelanocortin gene
The possible impact of the POMC gene on obesity was studied by sequencing the gene in 91
children with severe early-onset obesity (unpublished data). The variants detected are
presented in Figure 6 and Table 8.
Figure 6. The structure of the POMC gene and the locations of the variants detected. The variants chosen for
further determination of allele frequencies are underlined.
Table 8. Variants detected in the POMC gene in children with severe early-onset obesity (n=91).
Nucleotide Amino acid / location Heterozygous Homozygous
C7662T S68S 11 -
7676/7677ins9bp 73/74insSSG 13 1
C7726T L90L 1 -
C7965T A169A 11 -
A8021G E188G 2 -
C8246T 3’UTR 19 -
G8469C 3’UTR 1 -
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Three variants were chosen for determination of allele frequencies in 248 adult morbidly
obese subjects and 191 subjects from the background population (Table 9). No significant
differences in allele frequencies were detected between the groups studied.
Table 9. Minor allele frequencies of POMC variants in morbidly obese adults, children with severe early-onset
obesity and a background population sample.






73/74insSSG 0.042 0.082 0.068
E188G 0.014 0.011 0.003
G8469C 0.016 0.05 0.018
2 FUNCTIONAL STUDIES OF MC4R AND MC3R GENES
2.1 Functional properties of mutant melanocortin-4 receptors in vitro
The ability of MC4R to generate cAMP in response to increasing concentrations of α-MSH
was studied by co-transfecting 293T or 293H cells with wt or mutant MC4R and a cAMP
responsive TRH-luciferase promoter construct. Receptor mutations T112M, S127L, I226T
(study II) and M200V (unpublished data) were studied. The luciferase asay revealed
impaired response of the S127L mutant receptor to α-MSH (study II, Figure 2A). In study II,
the mutant receptors T112M, S127L and I226T were also tested for β-MSH and γ1-MSH. The
activity of the S127L mutant receptor was impaired for all peptides tested, while the other
mutants gave responses similar to the wt receptor (study II, Figure 2B-C). No difference was
detected between the different mutants and the wt receptor when test d for inhibition by
AGRP (study II, Figure 2D-E). The activity of the M200V receptor in response to α-MSH
(Figure 7A) and AGRP (Figure 7B) was similar compared to that of the wt receptor. The
S127L mutant was included in the later transfections as an inter al control of a receptor with
decreased signaling properties.
Cellular localization of the mutant and wt MC4-receptors was examined by
fluorescence microscopy. All mutants and the wt receptor could be detected on the cell
membrane by fluorescence microscopy (Figure 8 and study II, Figure 3A). Quantification of
mutant receptors T112M, S127L and I226T on the cell surface was also performed with
ELISA (study II, Figure 3B). It was shown that same amounts of mutant and wt receptors
were transported to the cell membrane.
2.2 Functional studies of the MC3R promoter
In study I, the variants that were located in UTRs were analyzed in silico by use of the
MatInspector program (Quandt et al. 1995). According to MatInspector, the -239A>G variant
was located in a consensus GATA transcription factor binding site (aaacaaGATAaaaact),
comprising nucleotides -244 to -228 of the MC3R gene (-239A>G major allele is underlined
in the consensus sequence).
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Figure 7. Luciferase reporter assay of receptor signaling. A) Responses of wt and mutant (S127L and M200V)
MC4R to different doses of α-MSH. B) Responses of wt and mutant MC4R to different doses of AGRP, in a
constant α-MSH concentration. Relative activity of the maximal receptor activity is shown.
Figure 8. Wt MC4R and the M200V mutant were transiently transfected to 293H cells. The receptors could be
detected on the cell surface by fluorescence microscopy.
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The ability of the -239A>G site in the MC3R promoter to bind GATA proteins was
assessed by use of EMSA. In the EMSA analyses, nuclear extracts containing GATA-4 and
GATA-6 proteins yielded a strong retarded band A with the wt probe MC3R (study I, Figure
1, lane 1), whereas the MC3Rmut oligonucleotide revealed only a weak protein-DNA
complex (study I, Figure 1, lanes 9 and 10). In competition assays, using an excess of
unlabelled MC3R or SF-1 oligonucleotide (known to harbor a consensus GATA binding site),
band A was clearly attenuated (study I, Figure 1, lanes 2, 3 and 5), indicating specific bind ng.
Competition with unlabelled MC3Rmut oligonucleotide did not change the formation of band
A (study I, Figure 1, lane 4). In supershift experiments, GATA-4 antibody abolished band A
indicating that GATA-4 is responsible for binding to the MC3R oligonucleotid . In contrast,
GATA-3 and GATA-6 antibodies did not change the protein binding pattern (study I, Figure
1, lanes 6, 7 and 8). Binding of GATA-4 was stronger to the wt oligonucleotide MC3R than to
the MC3Rmut oligonucleotide (containing the minor allele of -239A>G).
2.3 Functional studies of the MC4R promoter
The -439delGC site in the MC4R promoter was analysed in silico by MatInspector and
TFSearch software to search for important transcription factor binding sites that might be
altered by the deletion. Both programs predicted the deletion to be locatd immediately 3’
from a potential NHLH transcription-factor-binding E-box element (study III, Figure 1).
According to MatInspector and TFSearch software, the NHLH-binding site is d stroyed by
the -439delGC deletion.
Binding of NHLH2 to the MC4R promoter region containing the -439delGC mutation
was demonstrated by EMSA (study III, Figure 4). In the EMSA analyses, nuclear extracts
containing NHLH2 were shown to bind to both wt (MC4R-wt) and mutant MC4R (MC4R-
del) oligonucleotides, as well as to the µE2 control oligonucleotide harbouring an NHLH-
binding E-box site (Uittenbogaard et al. 1999) (study III, Figure 4).
The activities of the Mc4rwt or Mc4rdelGC promoters were compared by luciferase
reporter gene assays in HeLa and COS-1 cells. Reporter gene assays were also performed
with a mouse pituitary gonadotrope cell line, LβT2. The Mc4rdelGC construct had similar
luciferase activity as the Mc4rwt in all cells tested (data not shown). The activities of the
Mc4r promoter constructs were several fold higher when compared to theempty pGL3-basic
vector.
3 SNPS AND SNP HAPLOTYPES IN OBESITY CANDIDATE GENES
MC2R, MC3R, MC4R, MC5R, POMC AND ENPP1
In study IV, a series of SNPs in the MC2R-MC5R, POMC and ENPP1 genes were studied for
association with obesity. Twenty-five SNPs, including 2-7 SNPs in each gene were genotyped
in 246 morbidly obese Finns (BMI ≥ 40 kg/m2) and 481 lean subjects (BMI 20-25 kg/m2).
The SNPs and SNP haplotypes were tested for association with obesity and type 2 diabetes.
Allele frequencies differed significantly between obese and lean subjects for two SNPs
in the ENPP1 gene when tested by a chi-squared test; rs1800949 (minor allele frequencies
0.22 and 0.16 in cases vs. controls, P = 0.006) and rs943003 (minor allele frequencies 0.48
and 0.39 in cases vs. controls, P = 0.0009). When corrected for by false discovery rate, the
association remained significant for both SNPs rs1800949 and rs943003 (P-values 0.004 and
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0.008, respectively). These SNPs are part of a haplotype (rs1800949 C-rs943003 A), which
was observed more frequently in lean compared to obese subjects (P = 0.0007).
Suggestive associations were detected between the SNPs rs1541276 in the MC5R
gene, rs1926065 in the MC3R gene and obesity (P = 0.04 and P = 0.03, respectively), and
between SNPs rs2236700 in the MC5R gene, rs2118404 in the POMC gene, rs943003 in the
ENPP1 gene and type 2 diabetes (P = 0.03, P = 0.02 and P = 0.02, respectively). These
associations with type 2 diabetes were detected in the presence of morbid obesity. None of
these suggestive associations remained significant after correction for multiple testing.
ENPP1 SNPs rs1800949 and rs943003, located 5’ to the transcription start point and
in intron 1, were initially analyzed by TFSearch and TESS software. Both of these programs
predicted the rs1800949 SNP to be located in an Upstream stimulatory factor 1 (USF1)-
binding site and this site to be destroyed by the minor allele of the SNP. TFSearch predicted
the SNP rs943003 to be located in a Lymphoid transcription factor 1 (LyF-1) binding site,
whereas TESS predicted the binding sites for the following transcription factors to be located
at this position: E1A-associated protein p300, Olfactory neuron-specific transcription factor-1
(Olf-1) and Drosophila hunchback (Hb). Further analyses were performed with ConSite and
Con Real programs permitting analysis of conserved regulatory elements that are possibly
affected by SNPs. Using these programs, no conserved regulatory elements at the location of
the SNPs rs1800949 or rs943003 were detected when aligning human ENPP1 sequences to
the corresponding sequences from the species Mu musculus, Rattus norvegicus, Pan




1 GENETIC VARIATION IN THE MC4R GENE
1.1 Spectrum of MC4R mutations and polymorphisms
Mutations in the MC4R gene constitute the most common monogenic cause of human morbid
obesity, as demonstrated by several studies finding significant association between severe early-
onset obesity and MC4R mutations (Gu et al. 1999; Hinney et al. 1999; Sina et al. 1999;
Farooqi et al. 2000; Vaisse et al. 2000; Dubern et al. 2001; Mergen et al. 2001; Hebebrand et
al. 2002; Jacobson et al. 2002; Miraglia Del Giudice et al. 2002; Biebermann et al. 2003;
Donohoue et al. 2003; Farooqi et al. 2003; Hinney et al. 2003; Lubrano-Berthelier et al.
2003b; Marti et al. 2003; Santini et al. 2004; Buono et al. 2005; Larsen et al. 2005; Hinney et
al. 2006; Lubrano-Berthelier et al. 2006; Rong et al. 2006; Wang et al. 2006; Hainerová et al.
2007; Ochoa et al. 2007). In the present study, six pathogenic mutations in the MC4R gene
were identified among Finnish children with severe early-onset obesity. Four of these
mutations were located in the coding region of MC4R (308delT, two patients with S127L and
P299H). A deletion -439delGC in the promoter region of MC4R was identified in two
children. Additionally, a large number of polymorphisms were detected in the coding region
(V103I, T112M, M200V, I226T, I251L) and in non-coding regions (-1042C>T, -1005C>T, -
896C>T, -719G>A, -483C>T, -178A>C in the 5’UTR and 1059C>T in the 3’UTR) of the
MC4R gene in all cohorts studied.
In the present study, the prevalence of apparently pathogenic MC4R mutations among
Finnish children with severe early-onset obesity was 3.0%. This figure is close to the
frequency of 2.98%, which represents the combined number of MC4R mutations identified in
early-onset obesity from different study samples (Lubrano-Berthelier t al. 2006). Some
studies suggest a quite high population prevalence (2.35-2.5%) of MC4R mutations among
adult morbidly obese patients (Larsen et al. 2005; Lubrano-Berthelier et al. 2006). In line with
several other studies finding much lower frequencies of MC4R mutations among adult obese
patients (Jacobson et al. 2002; Branson et al. 2003; Santini et al. 2004; Hinney et al. 2006), no
pathogenic MC4R mutations were found among Finnish morbidly obese adult patients. It is
not known whether this implies amelioration of the phenotype upon aging in mutation
carriers, or reflects an adverse effect of the MC4R mutations on survival.
1.2 Genetic variants in the MC4R promoter region
The MC4R gene promoter was not characterized until 2003 and the initial screening of 431
obese subjects revealed no mutations (Lubrano-Berthelier et al. 2003a). In Finnish morbidly
obese children and adults several genetic variants were detected in non-coding regions of the
MC4R gene. Especially interesting is the -439delGC deletion, which was detected in two
children with severe early-onset obesity. The mutation could not be identified in 454 lean
controls.
The deletion is situated in the minimal promoter region of the MC4R gene (Lubrano-
Berthelier et al. 2003a), at a potential bHLH-binding E-box element, 12 nucleotides upstream
of the major transcription start point. Interestingly, as predicted by MatInspector and
TFSearch software, this E-box harbors a consensus-binding site for the NHLH transcription
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factors. The transcription factor NHLH2 was recently implicated in the regulation of body
weight in rodents, as Nhlh2 deficient mice demonstrate an obesity phenotype similar to that
seen in Mc4r deficient mice (Coyle et al. 2002). In addition, Jing et al. (2004) demonstrated
that in mice, Nhlh2 is expressed in all hypothalamic regions involved in body weight
regulation, including Mc4r and Lepr expressing neurons. Given the overlapping expression
patterns of Nhlh2 and Mc4r in the hypothalamus and the fact that the MC4R promoter
contains bHLH-binding sites (Lubrano-Berthelier et al. 2003a), it seems plausible that
NHLH2 could influence MC4R expression. It was therefore hypothesized, that the -439delGC
site identified in the present study could serve as an NHLH2 binding site, and that the two-
nucleotide deletion might affect binding of this transcription factor. This in turn could result
in altered promoter activity and gene expression.
By use of gel shifts assays it was demonstrated that the transcription factor NHLH2
indeed binds to the consensus E-box sequence at the -439delGC site in vitro. However,
reporter gene assays performed in three different cell lines, icluding a mouse pituitary cell
line, revealed no significant differences in mutant compared to wt MC4R promoter activities.
This might have several different explanations. First, the influence of the two-nucleotide
deletion on the function of the MC4R promoter may be too subtle to be monitored by transient
transfection experiments and yet have phenotypic effects in vivo. Second, it is possible that
the MC4R promoter fragment inserted in the reporter constructs was too short to adequately
reflect differences in promoter activities. Third, the in vitro cell models may lack important
cofactors that exist in vivo. Fourth, it is also possible that NHLH2 is not the transcription
factor that binds to this specific region in vivo, but some other E-box binding bHLH factor
may be more important for the regulation of the MC4R gene at this site.
1.3 Functional properties of MC4Rs and classification of mutations
Mutations in the MC4R include in-frame deletions, frameshift, nonsense and missense
mutations scattered throughout the coding sequence of the gene, impairing signaling through
the receptor by three major mechanisms, i.e. intracellular retention of the receptor leading to
reduced cell surface expression, mutations resulting in reduced receptor activity in response to
agonists and decrease in the constitutive activity of the receptor (Farooqi et al. 2003; Lubrano-
Berthelier et al. 2003b). In vitro functional studies of natural mutations have revealed specific
functional defects behind mutant MC4Rs (Gu et al. 1999; Ho and MacKenzie 1999; Farooqi et
al. 2000; Vaisse et al. 2000; Kobayashi et al. 2002; Biebermann et al. 2003; Donohoue et al.
2003; Farooqi et al. 2003; Hinney et al. 2003; Lubrano-Berthelier et al. 2003b; Nijenhuis et al.
2003; Tao and Segaloff 2003; Yeo et al. 2003; Lubrano-Berthelier et al. 2004; Santini et al.
2004; Larsen et al. 2005; Tao 2005; Hinney et al. 2006; Lubrano-Berthelier et al. 2006).
Dominant negative effects of the mutations have been excluded, suggesting haploinsufficiency
as the major mechanism behind the obesity phenotype (Yeo et al. 2003). In a recent study, it
was demonstrated that over 90% of inactivating MC4R mutations were located at evolutionary
highly conserved amino acid locations (Stäubert et al. 2007).
In this study functional properties of four MC4R variant receptors were investigated
(T112M, S127L, M200V and I226T), based on the facts that in our material the T112M,
S127L and M200V variants were present in obese individuals only and no comprehensiv
information on the functional properties of these receptors were available. As there is growing
evidence that α-MSH may not be the most important MC4R agonist in the brain (Mountjoy et
al. 1999; Millington et al. 2001; Harrold et al. 2003; Biebermann et al. 2006; Lee et al. 2006),
we took a novel approach and studied the signaling properties of the variant receptors, in
addition to stimulation with α-MSH, also with β-MSH and γ1-MSH. These studies confirmed
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the pathogenic role of the S127L mutation, showing decreased responses to all the agonists
tested. The data indicate that obesity in S127L carriers may, in addition to decreased signaling
in response to α-MSH, also be due to decreased signaling in response to β-MSH. In contrast,
γ1-MSH is a poor ligand for MC4R in vitro and it seems unlikely that the observed decreased
response to very high doses of γ1-MSH plays a significant role in the pathogenesis of obesity
in S127L carriers. We also tested the hypothesis that mutant MC4Rs could respond
differently, in a mutation dependent manner, to these peptides. The results do not, however,
support such a hypothesis. In contrast to the S127L mutation, the responses of th  T112M,
M200V and I226T variants did not differ from that of wt receptor. Thevariant receptors were
also tested for inhibition by AGRP, but the mutations did not affect AGRP mediated
inhibition of MC4R in vitro. Cell membrane localization of the variants T112M, S127L,
M200V and I226T did not differ from that of wt. This confirmed that the impaired function of
S127L is the result of a signaling defect and not a defect of transport to the cell membran .
While study II was in progress, Lubrano-Berthelier et al. (2003b) reported, in line with
the present data, that the S127L mutation was characterized by decreased activation of the
receptor by α-MSH and not by impaired cell surface expression. The S127L mutation was
also detected in compound heterozygous form in two subjects with severe, early-onset obesity
(Hinney et al. 2003). In contrast to study II and the study by Lubrano-Bertheli  et al., Hinney
and co-workers concluded that the S127L mutation led to increased constitutive activity of the
receptor, as they found a slight, twofold increase in basal S127L activity ompared to the wt
receptor (Hinney et al. 2003). Hinney et al. used a 1-hour cAMP assay  opposed to the 5-
hour transcriptional assay used in the present study, which might provide one explanation for
the differing results. However, importantly, in the study by Hinney et al. there was a major
shift to the right of the dose response curve, compatible with severely impaired function of the
S127L receptor (Hinney et al. 2003).
As the MC4R 308delT deletion is predicted to result in a grossly truncated receptor of
only 107 amino acids, we did not perform functional studies on this mutant receptor. It has
been previously shown that especially some C-terminal residues, which are totally absent
from the mutant 308delT receptor, are important in MC4R cell surface targeting
(VanLeeuwen et al. 2003).
Polymorphisms of the MC4R gene may modulate the obesity phenotype and some of
the gene variants have been implicated in common polygenic obesity (Rankinen et al. 2006).
For example, the V103I variant was shown to be negatively associated with obesity in three
recent meta-analyses (Geller et al. 2004; Heid et al. 2005; Young et al. 2007). Although
functional studies did not reveal differences between wt and variant eceptors, the
polymorphism was suggested to cause moderate gain of function of MC4R (Geller et al.
2004). It was also demonstrated that carriers of the variant allele I103 had significantly lower
BMI compared to those carrying the wt allele V103 (Heid et al. 2005; Young et al. 2007). In
addition, in a recent meta-analysis the I251L variant was shown to be negatively associated
with obesity (Stutzmann et al. 2007). In the present study, no significant differences in allele
frequencies of the V103I and I251L variants could be demonstrated between the groups due
to small sample sizes. However, the 103I and 251L alleles seem to more frequently present
among the background population if compared to the obese cohorts. In line with the present
data, the MC4R variant M200V was proposed to be a polymorphism with s milar signaling
properties as the wt receptor (Tao 2005; Hinney et al. 2006). The variant receptors V103I,
T112M, and I251L have also been shown to have normal signaling properties (Gu et al. 1999;
Ho and MacKenzie 1999; Vaisse et al. 2000; Lubrano-Berthelier et al. 2003b; Tao and
Segaloff 2005; Hinney et al. 2006). However, this was challenged by a recent study where
Hinney et al. found reduced cell surface expression and ligand binding by the T112M receptor
(Hinney et al. 2006).
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Recently, two schemes for the classification of different types of MC4R mutations
were proposed (Tao and Segaloff 2003; Govaerts et al. 2005). The classification of mutations
is based on the observation of a positive relationship between the presence of a functional
defect and both the onset of obesity and severity of the obesity phenotype (Govaerts et al.
2005). The genetic variants of the MC4R gene detected in Finnish obese patients were
classified according to the scheme proposed by Tao and Segaloff (2003) (Table 10).
According to that scheme the mutations can be divided into the five categories. Class I
mutations are null mutations producing no receptor due to defective syntheis and possibly
accelerated degradation of the defective protein. Class II mutations are intracellularly trapped
mutants, which are not transported to the cell membrane. Mutations belonging to class III are
defective in binding affinity and therefore have impaired agonist stimulated signaling
properties. Class IV mutants have normal ligand binding ability, but the signaling properties
are impaired. Variants with apparently normal function belong to class V.
Table 10. Classification of Finnish MC4R mutations according to the scheme proposed by Tao and Segaloff
(2003).
Mutation class MC4R mutation Functional properties Obesity phenotype
I 308delT Null mutation Severe early-onset obesity
II P299H Intracellular retention Severe early-onset obesity
IV S127L Signaling defective Severe early-onset obesity
V V103I Normal Negatively associated with
obesity, protective
V T112M Normal Not associated with obesity
V M200V Normal Not associated with obesity
V I226T Normal Not associated with obesity
V I251L Normal Not associated with obesity
- -439delGC Normal promoter activity Severe early-onset obesity
1.4 Genotype-phenotype correlations of MC4R mutations
In contrast to several other monogenic obesity syndromes, MC4R deficiency is not easily
detected even by careful clinical characterization of the patient, because of the lack of
additional clinical characteristics or biochemical abnormalities besides obesity (Mutch and
Clement 2006b).
The deletion 308delT (Class I) was identified in a 13.3-year-old girl, who began her
abnormal weight gain before the age of one year and whose current BMI is 45.9 kg/m2. She
was diagnosed with type 2 diabetes at the age of 13. No clear segregation pattern of the
obesity phenotype with the mutation could be detected in the family (Figure 4, page 36). The
index patient’s mother was shown to be a carrier of the 308delT mutation. She is currently
overweight and was severely obese in childhood. Several other members of the family are
overweight or obese, and in addition, several members of the family have type 2 diabetes.
The missense mutation P299H (Class II) was identified in a 9.3-year-old boy, whose
abnormal weight gain began in the second year of life. In line with previous phenotypic data
from other MC4R mutation carriers (Farooqi et al. 2003), the patient had severe fasting
hyperinsulinemia. No clear segregation of the mutation with the obesity phenotype could be
detected in the family, as one lean adult member of the family was shown to be a carrier of
the mutation (Figure 4, page 36).
The S127L mutation (Class IV) was detected in two patients, a 14.8-year-old boy
(index A) with a current BMI of 36.7 kg/m2 and a 12.5-year-old girl (index B) with a BMI of
33.6 kg/m2. The phenotype of index patient A was observed to be somewhat more severe than
the phenotype of index patient B. Index patient A’s abnormal weight gain began in the second
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year of life, whereas index patient B started abnormally gaining weiht at the age of five
years. In addition, index A had severe fasting hyperinsulinemia and presented with acanthosis
nigricans, which together point towards marked insulin resistance (Nguyen et al. 2001;
Hirschler et al. 2002). In family A, a segregation pattern compatible with dominant
inheritance of this mutation can be seen, as both mutation carriers are obese and the other
family members are lean (Figure 4, page 36). In contrast, in family B one lean sibling of the
index patient was shown to be a carrier of the mutation (Figure 4, page 36). The other
mutation carriers in family B are severely obese. Both S127L index patients were shown to be
carriers of the possibly protective gene variant V103I. It is unclear to what extent the effect of
the S127L mutation can be overcome by the positive effects of the V103I polymorphism. T i
might to some extent explain the variable obesity phenotypes observed in the families.
The index patients carrying the MC4R promoter deletion -439delGC, currently aged
13.8 and 10.1 years, are severely obese with BMIs of 33.5 kg/m2 and 31.2 kg/m2,
respectively. In both patients the abnormal weight gain began at the age of four years. Family
studies and weight chart data revealed that the -439delGC deletion-carryi g siblings of the
index patients were characterized by early-onset obesity, as opposed to non-carrier siblings,
whose weight charts demonstrated normal weight development. Other family members
carrying the mutation have been lean throughout adulthood. These mutation carrers had a
history of being overweight in childhood but this was not as pronounced as in the younger
generation.
In families with MC4R mutations, the transmission mode seems to be autosomal
dominant, although the penetrance of the disease can be incomplete. It has been demonstrated
that the carriers of homozygous mutations develop a more severe phenotype than
heterozygous patients (Farooqi et al. 2000; Lubrano-Berthelier et al. 2004; Dubern et al.
2007). The observation that severely obese members carrying wt alleles and lean carriers of
mutations can be found in families with MC4R mutations further complicates the assessment
of the genetic effects of these mutations. It is clear that environmental factors may have a
large impact on the development of morbid obesity. According to the “thrifty gene” theory,
the current environment might be more obesity-promoting for the children carrying MC4R
mutations (Hinney et al. 2006), compared with the environment in which the old r
generations grew up, thus having a large impact on the phenotype of young MC4R mutation
carriers. In line with this, Irani et al. (2005) demonstrated that hyperphagia is reduced and the
obesity phenotype of Mc4r deficient mice can be overcome if exercise is introduced at an
early stage. Furthermore, Mc4r deficient mice are not hyperphagic when fed a low-fat diet,
but hyperphagia is observed when they are fed diets containing an increased amount of fat
(Butler and Cone 2003). One interesting feature of MC4R mutations is that the phenotype of
mutation carriers tends to ameliorate with time. Adult mutation carriers report less intense
hunger feelings (Farooqi and O'Rahilly 2006).
It has previously been reported that MC4R mutation carriers are hyperinsulinemic in
childhood (Farooqi et al. 2003). This can also be noticed in several of the Finnish children
carrying MC4R mutations. The susceptibility for hyperinsulinemia is interesting in the light of
our finding of a patient with the MC4R 308delT deletion and early-onset type 2 diabetes.
Severe early-onset obesity, together with a familial predisposition for type 2 diabetes, might
explain the early-onset of the disease in this patient.
It has been suggested that MC4R mutation carriers have accelerated linear growth in
early childhood and an increase in lean mass and bone mineral density (Farooqi et al. 2003).
In general, slight acceleration in growth can be seen in Finnish patients carrying MC4R
mutations (standard deviation score, SDS of height varies from +0.2 to + .4). For example,
S127L index patient A was at the age of 12.8 years moderately advanced in skeletal
development with a bone age of 14.0 years. Similarly, the -439delGC index patient B was at
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the age of 10 years advanced in skeletal development with a bone age of 12.5. Thus they were
tall for their age as obese children in general are (Russell et al. 2001; Cameron et al. 2003).
The accelerated growth could be a consequence of early hyperinsulinemia seen in the patients
(Farooqi et al. 2003) and the increase in bone density may be explained by a decre se in bone
resorption (Elefteriou et al. 2005; Ahn et al. 2006).
An association between binge-eating disorder, i.e. compulsive overeating, and MC4R
mutations was suggested by Branson and co-workers in 2003. This theory has been lively
debated and so far has not been confirmed by others (Hebebrand et al. 2004; Tao and Segaloff
2005; Tortorella et al. 2005; Lubrano-Berthelier et al. 2006).
Based on these genotype-phenotype correlations of MC4R mutation carriers, the
severity of the receptor defect appears to be associated with the time of onset and the degree
of obesity (Table 11). Classification of MC4R mutations may provide a useful tool for
predicting the outcome of the disease (Govaerts et al. 2005).
Table 11. Genotype-phenotype correlations of MC4R mutations in Finnish patients: classification of mutations
and severity of the obesity phenotype.
Mutation class MC4R mutation Gender Age at onset of
abnormal weight
gain (years)
Age (years) BMI (kg/m2)
I 308delT Female <1 13.3 45.9
II P299H Male 2 9.3 39.2
IV S127L Male 2 14.8 36.7
IV S127L Female 5 12.5 33.6
- -439delGC Female 4 13.8 33.5
- -439delGC Male 4 10.1 31.2
2 GENETIC VARIATION IN THE MC3R, POMC AND NHLH2 GENES
Studies in animal models, human genome scans and case-control association studies all favor
the role of MC3R and POMC in obesity. As the role of NHLH2 has not been studied before in
human morbid obesity, the evidence of the possible importance of this gene in obesity stems
from animal studies. Table 12 summarizes the genetic variations ide tified in MC3R, POMC
and NHLH2 genes in the present study.
Allele frequencies of genetic variants (-239A>G, T6L and V81I) in the MC3R gene
were determined in the cohorts of morbidly obese adults, children with early-onset obesity
and a background population sample of healthy blood donors. The variants were common in
all groups studied and therefore don’t explain morbid obesity. Among morbidly obese adults,
the minor alleles of T6L and V81I variants were associated with hig er leptin levels and
higher insulin-glucose ratios. This was in line with the results by Hani and co-workers (2001),
who found marginally increased insulin-glucose ratios during an OGTT in normoglycemic
subjects carrying the T6L and V81I variant alleles.
The MC3R -239A>G variant is located in a consensus GATA transcription factor
binding site, as predicted by the MatInspector program. By use of gel shift a says we were
able to demonstrate that, of the various GATA proteins, GATA-4 is responsible for specific
binding to the MC3R -239A>G site. In addition, it was demonstrated that the binding of
GATA-4 is stronger to the wt allele than to the variant minor allele of -239A>G.
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Table 12. Genetic variations detected in the MC3R, POMC and NHLH2 genes in Finns.
Gene Genetic variation Type of variation Location within the
gene
Reference
MC3R -939G>C nucleotide substitution 5’UTR I
-911G>A nucleotide substitution 5’UTR I
-803T>C nucleotide substitution 5’UTR I
-373G>T nucleotide substitution 5’UTR I
-335G>A nucleotide substitution 5’UTR unpublished
-239A>G nucleotide substitution 5’UTR I, Li et al. 2000
-135insCT insertion 5’UTR unpublished
T6L missense exon 1 I, Li et al. 2000
Hani et al. 2001
V81I missense exon 1 I, Li et al. 2000
Hani et al. 2001
327G>A (P109P) silent nucleotide
substitution
exon 1 unpublished
354G>C (A118A) silent nucleotide
substitution
exon 1 unpublished
L249V missense exon 1 unpublished
1091G>A nucleotide substitution 3’UTR unpublished
POMC C7662T (S68S) silent nucleotide
substitution
exon 3, JP Hinney et al. 1998
73/74insSSG insertion exon 3, JP Hinney et al. 1998
C7726T (L90L) silent nucleotide
substitution
exon 3, JP Hinney et al. 1998
C7965T (A169A) silent nucleotide
substitution
exon 3, γ-LPH Hinney et al. 1998
E188G missense exon 3, γ-LPH Hinney et al. 1998
C8246T silent nucleotide
substitution
exon 3, 3’UTR Echwald et al. 1999
G8469C silent nucleotide
substitution
exon 3, 3’UTR unpublished
NHLH2 96C>T (L32L) silent nucleotide
substitution
exon 1 III
JP, joining peptide; γ-LPH, γ-lipotrophic hormone
A potentially interesting missense mutation, L249V, in the MC3R gene was identified
in one morbidly obese patient. The variant could not be detected in the background population
(n=312). Further studies of the L249V variant are needed in order to assess the functional
consequence and possible co-segregation of the mutation with obesity in family members.
Until now, only three rare MC3R mutations (A70T, M134I and I183N) have been described to
be associated with obesity (Lee et al. 2002; Rached et al. 2004; Tao and Segaloff 2004; Lee et
al. 2007). The first obesity associated MC3R mutation described was I183N, resulting in loss
of function of the receptor (Lee et al. 2002; Rached et al. 2004; Tao and Segaloff 2004). The
MC3R I183N mutation was identified in an obese 13-year-old girl and her father. Functional
analysis of this mutation revealed a defect in the agonists mediated ac ivation of the receptor
(Tao and Segaloff 2004). In the same study, the T6K and V81I variants were shown to have
normal signaling properties. In a recent study by Lee et al. (2007), the I183N mutation and
two additional mutations, A70T and M134I, were shown to result in impared signaling
activity of the receptor. These MC3R mutations were suggested to contribute as a
predisposing factor in childhood obesity (Lee et al. 2007).
Several known genetic variants were detected in the POMC gene (Hinney et al. 1998;
Echwald et al. 1999; Miraglia del Giudice et al. 2001; Rosmond et al. 2002; Feng et al. 2003;
Suviolahti et al. 2003b; Santoro et al. 2004; Chen et al. 2005). Two previously described
variants (73/74insSSG and E188G) and a novel polymorphism (G8469C) were select d for
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determination of allele frequencies. Allele frequencies of these variants did not differ between
morbidly obese adults, children with severe early-onset obesity and control subjects from the
background population.
In study III, no pathogenic mutations were found in the NHLH2 gene. However, one
silent nucleotide substitution 96C>T (L32L) was identified in two patients. Thus, mutations in
the NHLH2 gene have not been associated with severe early-onset obesity in humans, despite
attempts to identify NHLH2 human mutations (Brennan et al. 2006).
3 A RISK HAPLOTYPE FOR OBESITY IN THE ENPP1 GENE
The MC2R, MC3R, MC4R, MC5R, POMC and ENPP1 genes are all relevant candidates for
obesity. We took the approach of genotyping SNPs distributed over the coding and non-
coding regions of these genes and tested the possible association of these SNPs and SNP
haplotypes with obesity and type 2 diabetes.
The common allele of an ENPP1 haplotype, composed of the SNPs rs1800949 and
rs943003, was observed more frequently in lean compared to obese subjects. The ENPP1
variant K121Q has frequently been studied for association with insulin res stance, type 2
diabetes and obesity. In this study, no associations between the K121Q variant and obesity or
type 2 diabetes were detected, but other variants of the ENPP1 gene were associated with
obesity.
These two ENPP1 SNPs, rs1800949 and rs943003, do not represent functional
missense variants affecting the amino acid sequence of the protein. SNP rs1800949 is located
5’ to the transcription start point and rs943003 is located in the first intron of the ENPP1
gene. No conserved regulatory elements at the location of these SNPs were detected by use of
computational in silico analysis. These SNPs may nevertheless serve as regulatory elements
of the ENPP1 gene. Alternatively, these sites could be in LD with functional elemnts of the
ENPP1 gene or be in LD with a yet unidentified functional polymorphism in another gene.
In conclusion, an ENPP1 haplotype was found to be associated with morbid obesity in
Finnish adults.
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During the last ten years there has been remarkable progress in the f eld of obesity research.
The identification of rare monogenic defects in human genes, encoding proteins f the leptin-
melanocortin signaling system, has confirmed that inherited forms of human obesity indeed
exist. Mutations in the MC4R gene underlie 1-6% of morbid obesity worldwide, thus MC4R
deficiency represents the most common monogenic defect causing human obesity reported so
far (Vaisse et al. 2000; Farooqi and O'Rahilly 2006). Functional testing of mutant proteins has
become a valuable research tool in the evaluation of the consequences of a genetic defect. In
addition, knowledge about the importance of regulatory regions in gene expression i
continuously increasing.
The main achievement of this thesis was the identification of MC4R mutations in
Finnish patients. In total, six pathogenic mutations were identified, g ving a prevalence of 3%
for MC4R mutations in severe early-onset obesity. No obesity causing MC4R mutations were
found among Finnish patients with morbid adult-onset obesity. The in vitro functional
properties of these mutant receptors were elucidated and new insights in the function of the
MC4R gene were gained through studies of the promoter region.
Several common genetic variants were identified in the MC3R and POMC genes.
These polymorphisms do not explain morbid obesity, but the results indicate that some of
these genetic variations might be modifying factors in obesity, resulting in subtle changes in
obesity-related traits. Thus, the minor alleles of the common MC3R T6L and V81I variants
were found to be associated with higher leptin levels and higher insulin-gl cose ratios.
Furthermore, a risk haplotype for obesity in the ENPP1 gene was identified through an
approach of genotyping SNPs distributed over several candidate genes. An ENPP1 haplotype,
composed of SNPs rs1800949 and rs943003, was shown to be associated with morbid obesity
in adults. The MC3R, POMC and ENPP1 genes represent examples of susceptibility genes in
which genetic variants predisposing to obesity have been identified.
In conclusion, pathogenic mutations in the MC4R gene were shown to account for 3%
of cases with severe early-onset obesity in Finland. The severity of the MC4-receptor defect
appears to be associated with time of onset and the degree of obesity. Thus classification of
MC4R mutations may provide a useful tool when predicting the outcome of the disease. In
addition, several other genetic variants conferring suseptibility to obesity were detected in the
MC3R, MC4R, POMC and ENPP1 genes.
Although several genes involved in the regulation of energy balance and appetite have
been identified, the genetic basis of common obesity remains partly unsolved. The next goal
in the post-genome era is to further characterize the variation in the human genome and to
identify the factors underlying common, polygenic forms of obesity. It is probable that a
combination of several approaches, including genome-wide SNP scans, transcriptomics,
proteomics, metabolomics, pharmacogenomics and nutrigenomics are needed to unravel the
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